Please sign in to follow a disease.
Immune system disorder
MONDO:0005046A disorder resulting from an abnormality in the immune system.
Also known as: disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease or disorder, immune system disorder
12959 clinical trials for this condition and its sub-types, 151 tagged with Immune system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Immune system disorder
-
Autoimmune disease 313 trials · 4,033 incl. sub-types
47 sub-types
- Autoimmune disorder of the nervous system 47 trials · 1,060 incl. sub-types Sub-types →
- Autoimmune disorder of gastrointestinal tract 0 trials · 936 incl. sub-types Sub-types →
- Autoimmune disorder of endocrine system 1 trial · 925 incl. sub-types Sub-types →
- CNS demyelinating autoimmune disease 5 trials · 853 incl. sub-types Sub-types →
- Autoimmune disorder of musculoskeletal system 0 trials · 795 incl. sub-types Sub-types →
- Lupus erythematosus 39 trials · 548 incl. sub-types Sub-types →
- Scleroderma 47 trials · 305 incl. sub-types Sub-types →
- Autoimmune disorder of exocrine system 0 trials · 196 incl. sub-types Sub-types →
- Autoimmune disorder of blood 0 trials · 152 incl. sub-types Sub-types →
- Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types Sub-types →
- Vitiligo 100 trials Sub-types →
- Antiphospholipid syndrome 58 trials · 59 incl. sub-types Sub-types →
- Autoimmune bullous skin disease 7 trials · 55 incl. sub-types Sub-types →
- Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types Sub-types →
- Rheumatic fever 16 trials
- Overlapping connective tissue disease 2 trials · 15 incl. sub-types Sub-types →
- Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types Sub-types →
- Undifferentiated connective tissue syndrome 7 trials
- Autoimmune pulmonary alveolar proteinosis 6 trials
- Type III hypersensitivity disease 3 trials · 6 incl. sub-types Sub-types →
- Anti-glomerular basement membrane disease 5 trials
- Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types Sub-types →
- Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types Sub-types →
- Cryoglobulinemia 3 trials Sub-types →
- Susac syndrome 2 trials
- Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types Sub-types →
- Anti-neutrophil antibody associated vasculitis 1 trial
- Phacolytic glaucoma 1 trial
- Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types Sub-types →
- Jaccoud syndrome 0 trials
- Kimura disease 0 trials
- Reynolds syndrome 0 trials
- Autoerythrocyte sensitization syndrome 0 trials
- Autoimmune disease with susceptibility to mycobacterium tuberculosis 0 trials
- Autoimmune glomerulonephritis 0 trials
- Autoimmune pulmonary disease due to PD-1 deficiency 0 trials
- Autoimmune urticaria 0 trials
- Euthyroid Graves orbitopathy 0 trials
- Multisystem autoimmune disease due to IKAROS gain of function 0 trials
- Non-specific autoimmune brainstem encephalitis with characteristic antibodies 0 trials
- Non-specific autoimmune brainstem encephalitis without characteristic antibodies 0 trials
- Non-specific autoimmune cerebellar ataxia with characteristic antibodies 0 trials
- Non-specific autoimmune cerebellar ataxia without characteristic antibodies 0 trials
- Non-specific autoimmune supratentorial encephalitis with characteristic antibodies 0 trials
- Non-specific autoimmune supratentorial encephalitis without characteristic antibodies 0 trials
- Tempi syndrome 0 trials
- Type II hypersensitivity reaction disease 0 trials
-
Leukocyte disorder 6 trials · 3,572 incl. sub-types
23 sub-types
- B-cell neoplasm 304 trials · 3,167 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Leukopenia 6 trials · 78 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Eosinophil disorder 2 trials · 51 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Functional neutrophil defect 0 trials · 13 incl. sub-types Sub-types →
- Mast cell activation syndrome 8 trials · 9 incl. sub-types Sub-types →
- POEMS syndrome 8 trials
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types Sub-types →
- Thymoma type B 0 trials · 4 incl. sub-types Sub-types →
- Human granulocytic anaplasmosis 1 trial
- Pelger-Huet anomaly 0 trials
- Eosinophil peroxidase deficiency 0 trials
- Hereditary neutrophilia 0 trials
- Human monocytic ehrlichiosis 0 trials
- Leukostasis 0 trials
- Pituitary gland basophil adenoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
-
Immune system cancer 0 trials · 3,121 incl. sub-types
25 sub-types
- Bone marrow cancer 2 trials · 1,631 incl. sub-types Sub-types →
- Plasma cell myeloma 1,105 trials · 1,128 incl. sub-types Sub-types →
- Thymus cancer 10 trials · 225 incl. sub-types Sub-types →
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Lymphatic system cancer 4 trials · 69 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- B-cell childhood acute lymphoblastic leukemia 37 trials
- T-cell childhood acute lymphocytic leukemia 10 trials
- Waldeyer's ring cancer 0 trials · 8 incl. sub-types Sub-types →
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- Primary vitreoretinal large b-cell lymphoma 3 trials
- Indolent primary cutaneous B-cell lymphoma 1 trial · 2 incl. sub-types Sub-types →
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
- Breast diffuse large B-cell lymphoma 1 trial
- Colon Burkitt lymphoma 0 trials
- Colorectal diffuse large B-cell lymphoma 0 trials
- Gastric mantle cell lymphoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Mast cell sarcoma 0 trials
- Primary pulmonary diffuse large B-cell lymphoma 0 trials
- Small intestinal Burkitt lymphoma 0 trials
- Small intestinal diffuse large B-cell lymphoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
- Solitary plasmacytoma of chest wall 0 trials
- Thyroid gland diffuse large B-cell lymphoma 0 trials
-
Bone marrow disorder 18 trials · 1,761 incl. sub-types
7 sub-types
- Bone marrow neoplasm 3 trials · 1,631 incl. sub-types Sub-types →
- Polycythemia 9 trials · 99 incl. sub-types Sub-types →
- Bone marrow failure syndrome 48 trials Sub-types →
- Osteomyelitis 43 trials · 46 incl. sub-types Sub-types →
- Fanconi anemia 29 trials · 42 incl. sub-types Sub-types →
- Drachtman Weinblatt Sitarz syndrome 0 trials
- Premature ovarian failure 15 0 trials
-
Inflammatory bowel disease 429 trials · 1,079 incl. sub-types
40 sub-types
- Colitis 41 trials · 677 incl. sub-types Sub-types →
- Crohn disease 561 trials · 567 incl. sub-types Sub-types →
- Proctitis 2 trials · 21 incl. sub-types Sub-types →
- Inflammatory bowel disease 1 3 trials
- Undetermined colitis 3 trials
- Ulcerative proctosigmoiditis 2 trials
- ALPI-related inflammatory bowel disease 0 trials
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- TRIM22-related inflammatory bowel disease 0 trials
- Cap polyposis 0 trials
- Cutaneous photosensitivity-lethal colitis syndrome 0 trials
- Inflammatory bowel disease (infantile ulcerative colitis) 31, autosomal recessive 0 trials
- Inflammatory bowel disease 10 0 trials
- Inflammatory bowel disease 11 0 trials
- Inflammatory bowel disease 12 0 trials
- Inflammatory bowel disease 13 0 trials
- Inflammatory bowel disease 14 0 trials
- Inflammatory bowel disease 15 0 trials
- Inflammatory bowel disease 16 0 trials
- Inflammatory bowel disease 17 0 trials
- Inflammatory bowel disease 18 0 trials
- Inflammatory bowel disease 19 0 trials
- Inflammatory bowel disease 2 0 trials
- Inflammatory bowel disease 20 0 trials
- Inflammatory bowel disease 21 0 trials
- Inflammatory bowel disease 22 0 trials
- Inflammatory bowel disease 23 0 trials
- Inflammatory bowel disease 24 0 trials
- Inflammatory bowel disease 26 0 trials
- Inflammatory bowel disease 27 0 trials
- Inflammatory bowel disease 29 0 trials
- Inflammatory bowel disease 3 0 trials
- Inflammatory bowel disease 30 0 trials
- Inflammatory bowel disease 4 0 trials
- Inflammatory bowel disease 5 0 trials
- Inflammatory bowel disease 6 0 trials
- Inflammatory bowel disease 7 0 trials
- Inflammatory bowel disease 8 0 trials
- Inflammatory bowel disease 9 0 trials
- Neonatal inflammatory skin and bowel disease 0 trials Sub-types →
-
Hypersensitivity reaction disease 32 trials · 1,022 incl. sub-types
10 sub-types
- Allergic disease 178 trials · 966 incl. sub-types Sub-types →
- Anaphylaxis 26 trials · 27 incl. sub-types Sub-types →
- Type IV hypersensitivity disease 0 trials · 18 incl. sub-types Sub-types →
- Hypersensitivity vasculitis 0 trials · 16 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- IgE responsiveness, atopic 9 trials
- Type III hypersensitivity disease 3 trials · 6 incl. sub-types Sub-types →
- Progestogen hypersensitivity 3 trials
- Pseudoallergy 0 trials Sub-types →
- Type II hypersensitivity reaction disease 0 trials
-
Immunodeficiency disease 55 trials · 776 incl. sub-types
95 sub-types
- T-cell immunodeficiency 4 trials · 484 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Myalgic encephalomeyelitis/chronic fatigue syndrome 73 trials
- Combined immunodeficiency 3 trials · 57 incl. sub-types Sub-types →
- Complement deficiency 2 trials · 28 incl. sub-types Sub-types →
- X-linked lymphoproliferative syndrome 7 trials · 11 incl. sub-types Sub-types →
- GATA2 deficiency with susceptibility to MDS/AML 5 trials · 8 incl. sub-types Sub-types →
- Idiopathic CD4 lymphocytopenia 7 trials
- IKBKG-related immunodeficiency with or without ectodermal dysplasia 0 trials · 4 incl. sub-types Sub-types →
- Immunodeficiency due to selective anti-polysaccharide antibody deficiency 2 trials
- IRF4-related immune disorder 1 trial Sub-types →
- PTEN harmartoma tumor syndrome with immune disorder 1 trial
- Immunodeficiency 23 1 trial
- Immunodeficiency 31B 1 trial
- DNAJC21-related Shwachman Diamond syndrome 0 trials
- DOCK2 deficiency 0 trials
- FADD-related immunodeficiency 0 trials
- FASLG-related immunodeficiency 0 trials
- FNIP1-associated syndrome 0 trials
- Shwachman-Diamond syndrome 1 0 trials
- TFRC-related combined immunodeficiency 0 trials
- TNFRSF9-related immunodeficiency 0 trials Sub-types →
- Wiskott-Aldrich syndrome 2 0 trials
- Wiskott-Aldrich syndrome, autosomal dominant form 0 trials
- Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 0 trials
- Chronic mucocutaneous candidiasis and connective tissue disease due to JNK1 haploinsufficiency 0 trials
- Cryptosporidiosis-chronic cholangitis-liver disease syndrome 0 trials
- Hatipoglu immunodeficiency syndrome 0 trials
- Hypoproteinemia, hypercatabolic 0 trials
- Immune deficiency due to impaired neutrophil phagocytosis and migration 0 trials
- Immunodeficiency 101 (varicella zoster virus-specific) 0 trials
- Immunodeficiency 102 0 trials
- Immunodeficiency 106, susceptibility to viral infections 0 trials
- Immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection 0 trials
- Immunodeficiency 112 0 trials
- Immunodeficiency 113 with autoimmunity and autoinflammation 0 trials
- Immunodeficiency 114, folate-responsive 0 trials
- Immunodeficiency 115 with autoinflammation 0 trials
- Immunodeficiency 117 0 trials
- Immunodeficiency 118 0 trials
- Immunodeficiency 119 0 trials
- Immunodeficiency 11b with atopic dermatitis 0 trials
- Immunodeficiency 121 with autoinflammation 0 trials
- Immunodeficiency 122 0 trials
- Immunodeficiency 123 with HPV-related verrucosis 0 trials
- Immunodeficiency 125 0 trials
- Immunodeficiency 126, susceptibility to 0 trials
- Immunodeficiency 127 0 trials
- Immunodeficiency 128 0 trials
- Immunodeficiency 132b 0 trials
- Immunodeficiency 133 with ectodermal dysplasia with or without peripheral neuropathy 0 trials
- Immunodeficiency 134 (Epstein-Barr virus-specific) 0 trials
- Immunodeficiency 14b, autosomal recessive 0 trials
- Immunodeficiency 15a 0 trials
- Immunodeficiency 35 0 trials
- Immunodeficiency 45 0 trials
- Immunodeficiency 53 0 trials
- Immunodeficiency 57 0 trials
- Immunodeficiency 60 0 trials
- Immunodeficiency 62 0 trials
- Immunodeficiency 63 with lymphoproliferation and autoimmunity 0 trials
- Immunodeficiency 64 0 trials
- Immunodeficiency 65, susceptibility to viral infections 0 trials
- Immunodeficiency 66 0 trials
- Immunodeficiency 67 0 trials
- Immunodeficiency 69 0 trials
- Immunodeficiency 70 0 trials
- Immunodeficiency 72 with autoinflammation 0 trials
- Immunodeficiency 74, COVID-19-related, X-linked 0 trials
- Immunodeficiency 75 0 trials
- Immunodeficiency 76 0 trials
- Immunodeficiency 77 0 trials
- Immunodeficiency 78 with autoimmunity and developmental delay 0 trials
- Immunodeficiency 80 with or without congenital cardiomyopathy 0 trials
- Immunodeficiency 81 0 trials
- Immunodeficiency 82 with systemic inflammation 0 trials
- Immunodeficiency 84 0 trials
- Immunodeficiency 85 and autoimmunity 0 trials
- Immunodeficiency 86 0 trials
- Immunodeficiency 87 and autoimmunity 0 trials
- Immunodeficiency 88 0 trials
- Immunodeficiency 89 and autoimmunity 0 trials
- Immunodeficiency 91 and hyperinflammation 0 trials
- Immunodeficiency 92 0 trials
- Immunodeficiency 93 and hypertrophic cardiomyopathy 0 trials
- Immunodeficiency 95 0 trials
- Immunodeficiency 96 0 trials
- Immunodeficiency 97 with autoinflammation 0 trials
- Immunodeficiency 98 with autoinflammation, X-linked 0 trials
- Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias 0 trials
- Immunodeficiency due to CD25 deficiency 0 trials
- Lymphoproliferative syndrome 1 0 trials
- Primary immunodeficiency due to calcium channel deficiency 0 trials
- Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency 0 trials
- Pyogenic bacterial infections due to MyD88 deficiency 0 trials
-
Lymphoid system disorder 1 trial · 744 incl. sub-types
5 sub-types
- Lymphatic system disorder 30 trials · 707 incl. sub-types Sub-types →
- Tonsillitis 23 trials · 27 incl. sub-types Sub-types →
- Waldeyer's ring cancer 0 trials · 8 incl. sub-types Sub-types →
- Tonsil neoplasm 0 trials · 8 incl. sub-types Sub-types →
- Peritonsillar abscess 4 trials
-
Psoriasis 379 trials
3 sub-types
- Pustular psoriasis 6 trials · 39 incl. sub-types Sub-types →
- Guttate psoriasis 2 trials
- Psoriasis 2 0 trials
-
Inborn error of immunity 121 trials · 343 incl. sub-types
40 sub-types
- Lymphoproliferative syndrome 69 trials · 99 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Complement deficiency 2 trials · 28 incl. sub-types Sub-types →
- Hereditary hemophagocytic lymphohistiocytosis 8 trials · 16 incl. sub-types Sub-types →
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Familial isolated congenital asplenia 6 trials
- Chronic mucocutaneous candidiasis 4 trials Sub-types →
- Immunoglobulin heavy chain deficiency 0 trials · 2 incl. sub-types Sub-types →
- A20 haploinsufficiency 1 trial
- BENTA disease 1 trial
- Immuno-osseous dysplasia 0 trials · 1 incl. sub-types Sub-types →
- Immunodysregulation with variable immunodeficiency and autoimmunity 1 trial
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- NK cell deficiency 0 trials
- Say-Barber-Miller syndrome 0 trials
- T cell and NK cell immunodeficiency 0 trials
- T-cell immunodeficiency with epidermodysplasia verruciformis 0 trials
- X-linked immunoneurologic disorder 0 trials
- Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity 0 trials
- Combined immunodeficiency due to moesin deficiency 0 trials
- Combined immunodeficiency with faciooculoskeletal anomalies 0 trials
- Dendritic cell deficiency 0 trials
- Ectodermal dysplasia and immune deficiency 0 trials Sub-types →
- Hepatic veno-occlusive disease-immunodeficiency syndrome 0 trials
- Immune dysregulation with immunodeficiency due to AIOLOS haploinsufficiency 0 trials
- Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome 0 trials
- Immunodeficiency 28 0 trials
- Immunodeficiency 33 0 trials
- Immunodeficiency 37 0 trials Sub-types →
- Immunodeficiency 39 0 trials
- Immunodeficiency 47 0 trials
- Immunodeficiency 49 0 trials
- Immunodeficiency with defective T-cell response to interleukin 1 0 trials
- Immunodeficiency, X-linked, with deficiency of 115,000 Dalton surface glycoprotein 0 trials
- Inflammatory bowel disease-recurrent sinopulmonary infections syndrome 0 trials
- Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 0 trials
- Properdin deficiency, X-linked 0 trials
- Recurrent infections associated with rare immunoglobulin isotypes deficiency 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
-
Graft versus host disease 186 trials · 300 incl. sub-types
2 sub-types
- Chronic graft versus host disease 118 trials
- Acute graft versus host disease 86 trials
-
Thymus gland disorder 1 trial · 240 incl. sub-types
3 sub-types
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Ectopic thymus 0 trials
- Thymic dysplasia 0 trials
-
Spondyloarthropathy 121 trials · 198 incl. sub-types
3 sub-types
- Ankylosing spondylitis 109 trials · 113 incl. sub-types Sub-types →
- Kummell disease 1 trial
- Hypermobility of coccyx 0 trials
-
Thrombocytopenic purpura 8 trials · 116 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
-
Granulomatosis with polyangiitis 95 trials · 115 incl. sub-types
1 sub-type
-
Phagocytic cell dysfunction 1 trial · 76 incl. sub-types
7 sub-types
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Defective phagocytic cell engulfment 0 trials · 37 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Defective phagocytic cell chemotaxis 0 trials
- Defective phagocytic cell opsonization 0 trials
- Familial lipochrome histiocytosis 0 trials
- Phagocytosis, plasma-related defect 1N 0 trials
-
Cytokine release syndrome 33 trials
-
Immunoproliferative disorder 18 trials
-
Familial Mediterranean fever 15 trials
2 sub-types
-
Immunodeficiency-related disorder 1 trial · 15 incl. sub-types
1 sub-type
- AIDS-related disorder 3 trials · 14 incl. sub-types Sub-types →
-
Twin to twin transfusion syndrome 14 trials
1 sub-type
-
22q11.2 deletion syndrome 7 trials · 13 incl. sub-types
4 sub-types
- DiGeorge syndrome 11 trials
- Velocardiofacial syndrome 4 trials
- Chromosome 22q11.2 deletion syndrome, distal 0 trials
- Congenital unilateral hypoplasia of depressor anguli oris 0 trials
-
Cryopyrin-associated periodic syndrome 10 trials
3 sub-types
- CINCA syndrome 4 trials
- Muckle-Wells syndrome 3 trials
- Familial cold autoinflammatory syndrome 3 trials Sub-types →
-
Acquired immunodeficiency 5 trials
2 sub-types
- Good syndrome 0 trials
- Acquired adult-onset immunodeficiency 0 trials
-
Anti-HLA hyperimmunization 3 trials
-
6 sub-types
- Proteasome-associated autoinflammatory syndrome 1 1 trial
- Proteasome-associated autoinflammatory syndrome 2 0 trials
- Proteasome-associated autoinflammatory syndrome 3 0 trials
- Proteasome-associated autoinflammatory syndrome 4 0 trials
- Proteasome-associated autoinflammatory syndrome 5 0 trials
- Proteasome-associated autoinflammatory syndrome 6 0 trials
-
Roifman syndrome 1 trial
-
Aggressive insulitis 1 trial
-
Transcobalamin II deficiency 1 trial
-
CADINS disease 0 trials
-
Vici syndrome 0 trials
-
Autosomal recessive osteopetrosis 7 0 trials
-
Benign insulitis 0 trials
-
Cytokine receptor deficiency 0 trials
-
Epidermodysplasia verruciformis 0 trials
1 sub-type
-
Erythroderma desquamativum 0 trials
-
Immune system organ benign neoplasm 0 trials
3 sub-types
- Benign neoplasm of lymph node 0 trials
- Benign neoplasm of spleen 0 trials Sub-types →
- Benign neoplasm of thymus 0 trials Sub-types →
Most studied deeper sub-types
Showing the 400 most recently updated of 1675 trials in this tab.
-
Can feeding allergens to toddlers build lasting food allergy tolerance?
Cure Not yet recruitingResearchers test whether daily oral immunotherapy can safely treat food allergy in children aged 0 to 2 with peanut, tree nut, or sesame allergy. Half the children receive the therapy, starting with tiny amounts of the allergen and building up over about six months, then a year o…
Sponsor: Copenhagen Studies on Asthma in Childhood • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Can a pill rebuild the Brain's insulation? MS trial puts remyelination to the test
Cure Not yet recruitingResearchers are testing an experimental oral drug called PRO-1562 in healthy adults and in adults with relapsing multiple sclerosis who also have long-term vision damage from chronic optic neuropathy. The trial has two parts: a phase 1 safety and absorption study in healthy volun…
Phase 1/2 • Sponsor: Progentos Therapeutics • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Experimental cell therapy targets Hard-to-Treat lymphoma
Cure Not yet recruitingResearchers are testing an experimental cell therapy called CT1190B in adults with large B-cell lymphoma that has returned or stopped responding to treatment. The trial enrolls up to 68 people aged 18 to 75 and gives the therapy by intravenous infusion. The main goals are to chec…
Phase 1/2 • Sponsor: UCARsgen Biotech Limited • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
Cure Not yet recruitingThis phase 2 trial is testing whether a single infusion of a patient's own genetically modified immune cells, called C-CAR168, can safely and effectively treat lupus nephritis that has not responded to standard therapies. The cells are designed to target and eliminate specific im…
Phase 2 • Sponsor: AbelZeta Inc. • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Could bone marrow from deceased donors cure blood cancers?
Cure Not yet recruitingThis study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…
Sponsor: Ossium Health, Inc. • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can CRISPR-Edited cells stop autoimmune attacks on the brain?
Cure Not yet recruitingThis trial tests a therapy called CTX112 in adults with severe neurologic autoimmune diseases, including progressive multiple sclerosis, neuromyelitis optica, and stiff-person syndrome. CTX112 uses donor T cells edited with CRISPR to target and deplete B cells, which are thought …
Phase 1/2 • Sponsor: CRISPR Therapeutics • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Can a single CAR-T infusion reset the immune system and stop lupus kidney damage?
Cure Not yet recruitingThis early-phase trial tests whether a single infusion of CD19 CAR-T cells, called TranspoCART19, is safe and can push severe lupus nephritis into remission. Lupus nephritis is a serious kidney complication of lupus that often resists standard treatments. Ten adults with refracto…
Phase 1/2 • Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz • Aim: Cure
Last updated Sep 04, 2026 00:00 UTC
-
Can a new drug combo make stem cell transplants safer for frail AML patients?
Cure Not yet recruitingThis trial is testing whether a new conditioning regimen, called VABu, can improve outcomes for adults with acute myeloid leukemia (AML) who are in first remission but are too frail for standard transplant prep. The regimen combines venetoclax, azacitidine (or decitabine), and bu…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can a pill and injection combo beat AML without harsh chemo?
Cure Not yet recruitingThis trial tests a combination of two drugs, azacitidine and venetoclax, as the first treatment for young, fit adults (ages 18-50) with newly diagnosed acute myeloid leukemia (AML). The goal is to see how many patients achieve complete remission after one or two cycles of this th…
Phase 2 • Sponsor: Pakistan Blood and Marrow Transplant (PBMT) Group • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
One-shot CAR-T therapy takes on stem cell transplant for multiple myeloma
Cure Not yet recruitingThis phase 3 trial tests whether a single infusion of AZD0120, a CAR-T cell therapy that targets two proteins on myeloma cells, can outperform the standard approach of high-dose chemotherapy followed by a stem cell transplant. The study enrolls adults newly diagnosed with multipl…
Phase 3 • Sponsor: AstraZeneca • Aim: Cure
Last updated Aug 01, 2026 00:00 UTC
-
Can a smart immune cell with a kill switch beat tough lymphomas?
Cure Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Phase 1 • Sponsor: The Methodist Hospital Research Institute • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
Can a single infusion of engineered immune cells beat back hard-to-treat multiple myeloma?
Cure Not yet recruitingThis early-stage trial is testing an experimental therapy called KIV-318 for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. KIV-318 is a type of CAR-T cell therapy that reprograms a patient's own immune cells to recognize …
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
Can a fourth drug tip the scales against an aggressive leukemia?
Cure Not yet recruitingThis trial is testing whether adding venetoclax to standard intensive chemotherapy plus midostaurin can improve outcomes for adults with a type of acute myeloid leukemia that has a FLT3 mutation. The study enrolls people aged 18 to 70 with newly diagnosed disease who are healthy …
Phase 1/2 • Sponsor: University Hospital, Bordeaux • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
Can a CMV-Based vaccine teach the body to fight HIV?
Vaccine Not yet recruitingThis phase 1 trial tests a higher dose of the experimental HIV vaccine VIR-1388 in about 12 adults aged 18 to 55 who already carry cytomegalovirus (CMV). The vaccine uses a weakened CMV virus to deliver HIV proteins, aiming to trigger a strong immune response. Participants receiv…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 05, 2026 00:00 UTC
-
Under-the-Skin MS drug: can a shot replace an IV drip?
Disease control Not yet recruitingResearchers are observing how satisfied people with relapsing-remitting multiple sclerosis are when they receive ocrelizumab as an injection under the skin instead of an intravenous infusion. The study follows about 1,800 participants across multiple countries for 12 months, incl…
Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Triple-Drug combo aims to deepen myeloma response before transplant
Disease control Not yet recruitingResearchers are testing whether adding an experimental drug called F182112 to isatuximab and lenalidomide is safe and can help people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The trial enrolls about 10 adults aged 18 to 70. Participants r…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an experimental pill help teenagers with vitiligo?
Disease control Not yet recruitingResearchers are testing an experimental oral drug called VC005 in teenagers aged 12 to 17 who have non-segmental vitiligo, a condition where patches of skin lose their color. The study measures how the drug moves through the body and checks for safety over up to 24 weeks of treat…
Phase 1/2 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can rituximab infusions keep scleroderma lungs stable?
Disease control Not yet recruitingResearchers test whether rituximab helps maintain lung function in adults with systemic sclerosis and interstitial lung disease whose disease has stabilized after initial rituximab treatment. Participants receive rituximab or placebo infusions at months 0, 6, and 12. The main mea…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a liposomal drug combo improve AML treatment for older adults?
Disease control Not yet recruitingResearchers are testing a three-drug regimen called VAM for older or unfit adults with newly diagnosed acute myeloid leukemia (AML). The regimen combines liposomal mitoxantrone, azacitidine, and venetoclax. The trial aims to find the safest and most tolerable dose of liposomal mi…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Not yet recruitingThis study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …
Phase 3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an injected biologic cut steroid Flare-Ups in a Tough-to-Treat asthma complication?
Disease control Not yet recruitingResearchers are studying depemokimab, an injected biologic drug, in adults aged 18 to 75 who have allergic bronchopulmonary aspergillosis (ABPA) along with severe eosinophilic asthma. The study tracks how many asthma attacks need systemic steroids and whether participants' qualit…
Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered yeast pill takes on superbug c. diff in first human trial
Disease control Not yet recruitingThis early-stage trial tests an oral capsule containing a genetically modified probiotic yeast designed to neutralize toxins produced by C. diff bacteria. The study first evaluates safety in healthy adults, then in people at risk for recurrent C. diff infection. Participants take…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a single infusion tame tough lupus?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called SNC116 in people with refractory systemic lupus erythematosus (SLE), a form of lupus that hasn't improved with standard treatments. The study aims to see if a single intravenous infusion of SNC116 is safe and tolerable…
Early phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new pill outsmart Drug-Resistant leukemia?
Disease control Not yet recruitingThis phase 2 trial tests an oral drug called nemtabrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has stopped responding to other targeted therapies. Participants take nemtabrutinib once daily in 28-day cycles until the …
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug shorten Guillain-Barré recovery?
Disease control Not yet recruitingThis trial tests whether efgartigimod, a drug that lowers harmful antibody levels, can improve recovery in people with Guillain-Barré syndrome (GBS), a rare nerve condition that can cause weakness and paralysis. Adults aged 18 to 70 with recent GBS onset will receive either efgar…
Phase 2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Which biologic works best first for ulcerative colitis? major trial aims to find out
Disease control Not yet recruitingThis study compares four different sequences of biologic drugs (infliximab, filgotinib, ustekinumab, and vedolizumab) in 240 adults with moderate to severe ulcerative colitis. The goal is to see which order of treatments works best to achieve and maintain remission without steroi…
Phase 4 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Stem cell infusions put to the test against a tough transplant complication
Disease control Not yet recruitingResearchers are testing whether infusions of bone marrow-derived mesenchymal stem cells, called MesenCell, are safe for adults with moderate or severe chronic graft-versus-host disease that has not responded to steroids and other standard treatments. The trial enrolls up to 20 pe…
Phase 1 • Sponsor: Pontifícia Universidade Católica do Paraná • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Head-to-Head: which JAK inhibitor wins for myelofibrosis patients with low blood counts?
Disease control Not yet recruitingThis study compares two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug does a better job at shrinking the spleen and reducing the need for blood transfusions. About 268 particip…
Phase 4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
One-Time CAR-T infusion tested against progressive MS
Disease control Not yet recruitingResearchers are testing a one-time CAR-T cell therapy called C-CAR168 in adults with progressive multiple sclerosis that has not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to target two proteins, and is given as a single intravenou…
Phase 1/2 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Apps and wearables join forces to tackle psoriatic arthritis
Disease control Not yet recruitingThis study tests a digital health program designed to support people with psoriatic arthritis in managing their condition. Participants use a mobile app for symptom tracking and lifestyle tips, plus tools for sleep, stress, and physical activity, along with a smartwatch. The goal…
Sponsor: Sociedade Portuguesa de Reumatologia • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a second antibody drug help Guillain-Barré patients walk again sooner?
Disease control Not yet recruitingGuillain-Barré syndrome (GBS) is a rare condition where the immune system attacks nerves, causing weakness that can progress to paralysis. Standard treatment is intravenous immunoglobulin (IVIg), but recovery is often slow. This phase 2 trial tests whether adding an experimental …
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a liquid diet calm Crohn's in kids?
Disease control Not yet recruitingResearchers at Assiut University Children Hospital are studying whether a specially prepared medical milk formula called Modulen IBD can bring Crohn's disease into remission and keep it there in children and teenagers. About 40 young patients with mild to moderate active Crohn's …
Sponsor: Assiut University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can early symptom relief predict who stays on IBD biologic?
Disease control Not yet recruitingResearchers are tracking how long adults with moderate to severe Crohn's disease or ulcerative colitis keep taking guselkumab, a biologic drug, in routine care. The study follows about 400 people who start the treatment and records when they stop. It also checks whether early imp…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a daily liquid medicine calm severe eczema in toddlers and preschoolers?
Disease control Not yet recruitingResearchers are testing whether abrocitinib, an oral medicine taken once daily as a liquid, safely improves moderate-to-severe eczema in children aged 2 to under 6. About 90 children with a documented eczema diagnosis for at least a year will join. Two out of three will receive a…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug ATTO-1091 put to the test for safety in ulcerative colitis
Disease control Not yet recruitingResearchers are running a phase 1 trial to find out how safe and tolerable ATTO-1091 is in healthy adults and in people with ulcerative colitis. The study also measures how long the drug stays in the body. About 96 participants will receive either ATTO-1091 or a placebo, visit th…
Phase 1 • Sponsor: Attovia Therapeutics Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Leukemia shot could replace long IV drips
Disease control Not yet recruitingThis study tests if a shot (subcutaneous) of the drug blinatumomab works as well as the standard IV drip for adults with a certain type of leukemia (Ph-negative B-cell ALL). About 560 people who are in remission after initial chemo will get either the shot or the IV, along with m…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Antiparasitic drug tested as new weapon against ulcerative colitis
Disease control Not yet recruitingResearchers are testing whether nitazoxanide, an antiparasitic drug with anti-inflammatory properties, can help people with mild-to-moderate ulcerative colitis when added to their usual treatment. The trial enrolls adults aged 18 to 65 with active disease and stable therapy. Over…
Phase 2/3 • Sponsor: Tanta University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new pill outperform standard care for a tough transplant complication?
Disease control Not yet recruitingThis phase 3 trial is testing whether the oral drug belumosudil works better than the best available therapy for people aged 12 and older with chronic graft-versus-host disease (cGVHD) that has not improved or has returned after 2 to 5 prior treatments. Participants are randomly …
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a Lab-Made antibody quiet the immune attack behind Sjögren's syndrome?
Disease control Not yet recruitingResearchers are testing an experimental antibody called JH013 in adults with primary Sjögren's syndrome, a condition where the immune system attacks moisture-producing glands and other tissues. The trial has two parts: one gives a single injection at increasing doses, and the oth…
Phase 1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug BL-M08D1 joins standard therapy in fight against aggressive lymphoma
Disease control Not yet recruitingResearchers are testing an experimental drug called BL-M08D1 alongside standard immunochemotherapy in adults with diffuse large B-cell lymphoma. The trial enrolls about 204 people aged 18 to 75 whose cancer has at least one measurable lesion. Participants receive BL-M08D1 plus a …
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a single drug tame multiple autoimmune diseases?
Disease control Not yet recruitingThis trial tests an experimental drug called PF-08154225 in people with autoimmune diseases like lupus, rheumatoid arthritis, myositis, or scleroderma. The drug aims to calm the immune system, which mistakenly attacks healthy cells in these conditions. Participants receive the dr…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a single injection tame stubborn multiple sclerosis?
Disease control Not yet recruitingThis early-stage trial is testing an investigational injection called GT802 in people with relapsing or refractory multiple sclerosis (MS) — meaning their disease is active despite standard treatments. The study aims to check whether GT802 is safe and to get a first look at wheth…
Early phase 1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Leukemia combo shot and pill shows promise in early trial
Disease control Not yet recruitingThis Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a bispecific antibody wipe out residual leukemia cells in High-Risk CLL?
Disease control Not yet recruitingResearchers are testing whether adding epcoritamab can help high-risk chronic lymphocytic leukemia (CLL) patients who are already taking a BTK inhibitor clear remaining cancer cells. The trial enrolls 24 adults with CLL and specific risk factors such as a 17p deletion, TP53 mutat…
Phase 2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can an antibody that blocks a immune protein ease myasthenia gravis?
Disease control Not yet recruitingResearchers are testing an experimental antibody called EA5 in adults with generalized myasthenia gravis whose blood contains antibodies against the acetylcholine receptor and who have not tried complement inhibitor drugs. EA5 targets complement protein C5, part of the immune cas…
Phase 1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Two-Drug combo targets tough Non-Hodgkin's lymphoma
Disease control Not yet recruitingResearchers are testing two experimental drugs, SCTB35 and SCTB41, in adults with B-cell non-Hodgkin's lymphoma that has returned or stopped responding to at least two prior treatments. Participants receive the drugs together, with or without chemotherapy, to find a safe dose and…
Phase 1/2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Cancer drug tested against deadly infant heart disease
Disease control Not yet recruitingResearchers are testing whether trametinib, an FDA-approved cancer drug, can help infants with RASopathies who have a severe, life-threatening heart condition called hypertrophic cardiomyopathy. The trial enrolls about 25 babies with a confirmed genetic diagnosis. Participants re…
Phase 3 • Sponsor: Carelon Research • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
Disease control Not yet recruitingThis phase II trial is testing whether a planned dose reduction of the targeted therapy zanubrutinib can maintain control of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) while reducing long-term side effects in patients aged 80 and older who have not yet…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can two immune boosters outsmart follicular lymphoma without chemo?
Disease control Not yet recruitingThis phase II trial is testing whether combining two lab-made antibodies, tafasitamab and rituximab, can help people with newly diagnosed follicular lymphoma achieve complete remission. Both antibodies are designed to help the immune system recognize and attack cancer cells. The …
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a pill replace steroids for lupus flares?
Disease control Not yet recruitingResearchers are testing whether ivarmacitinib, an oral drug, works as well as prednisone for controlling arthritis and rash in adults with mild-to-moderate lupus. About 294 participants receive either ivarmacitinib or prednisone for 24 weeks. The goal is to see if ivarmacitinib c…
Phase 2/3 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Heart risk in rheumatoid arthritis: could a blood vessel drug help?
Disease control Not yet recruitingThis trial tests whether adding nicorandil, a drug that widens blood vessels, to standard rheumatoid arthritis (RA) treatment can reduce the buildup of plaque in arteries. People with RA have a higher risk of atherosclerosis, which can lead to heart attacks and strokes. Researche…
Phase 3 • Sponsor: Tanta University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new drug combo reach lymphoma hiding in the brain?
Disease control Not yet recruitingResearchers are testing whether adding pirtobrutinib to methotrexate and standard chemoimmunotherapy can help people with diffuse large B-cell lymphoma that has spread to the central nervous system. The trial enrolls about 24 people aged 14 to 80 whose lymphoma involves the brain…
Phase 2 • Sponsor: Pengpeng Xu • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new injection tame wheat allergy?
Disease control Not yet recruitingResearchers are testing an experimental injectable drug called LP-003 in people with wheat allergy that triggers allergic reactions during exercise. The Phase II trial enrolls 12 participants aged 12 to 60 who have a history of wheat or gluten allergy and react to a small amount …
Phase 2 • Sponsor: Longbio Pharma (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Dual-Pronged CAR T-Cell therapy takes aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis phase 1 trial tests a new cell therapy called KITE-753 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. KITE-753 is made from a patient's own immune cells, which are modified to recognize and attack leuke…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental drug F182112 tested against Hard-to-Treat blood disorder
Disease control Not yet recruitingResearchers are testing an experimental intravenous drug called F182112 in adults with autoimmune hemolytic anemia that has returned or resisted multiple treatments. The trial enrolls about 12 people and gives the drug at three increasing dose levels to check safety, tolerability…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could a simple sugar ease Crohn's? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial tests whether an oral supplement called N-acetylglucosamine (GlcNAc) can safely help control Crohn's disease in the ileum or ileocolon. Forty adults with stable Crohn's will receive either GlcNAc or a placebo for 6 weeks, then switch after a washout period. The…
Phase 2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for AML patients: experimental drug IPN60340 enters key trial
Disease control Not yet recruitingThis study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part…
Phase 2/3 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a Three-Drug combo erase mantle cell lymphoma without chemotherapy?
Disease control Not yet recruitingResearchers are testing whether a combination of three drugs, zanubrutinib, obinutuzumab, and sonrotoclax (called BOSon), can effectively treat mantle cell lymphoma in people who have not had prior treatment and are not eligible for a stem cell transplant. The study will enroll a…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Oral drug combo targets myeloma that escaped the bone marrow
Disease control Not yet recruitingResearchers are testing an experimental oral drug called HP-001 alongside dexamethasone in adults whose multiple myeloma has returned after treatment and has formed tumors outside the bone marrow. Participants take HP-001 capsules once daily for 10 days of each 28-day cycle, plus…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could a common antibiotic ease Kids' bowel disease?
Disease control Not yet recruitingThis study tests whether oral vancomycin, an antibiotic, can help children aged 6-15 with inflammatory bowel disease (IBD), especially types linked to liver problems. About 140 kids will either get vancomycin plus standard care or standard care alone for up to a year. Researchers…
Phase 2 • Sponsor: Tampere University Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can an old malaria drug make resistant leukemia vulnerable again?
Disease control Not yet recruitingResearchers are testing whether adding hydroxychloroquine to oral decitabine and venetoclax helps adults with acute myeloid leukemia (AML) that has relapsed or stopped responding to similar treatment. The study enrolls about 18 people with relapsed or refractory AML, or newly dia…
Phase 1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New Three-Drug cocktail aims to beat aggressive leukemia
Disease control Not yet recruitingThis study tests a new combination of three drugs—revumenib, azacitidine, and venetoclax—in people newly diagnosed with a specific, hard-to-treat leukemia called KMT2A-rearranged AML. The goal is to see if this cocktail can help more patients achieve remission with fewer side eff…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Two pills, one goal: a Time-Limited oral combo takes aim at returning blood cancer
Disease control Not yet recruitingResearchers are testing whether a fixed course of two oral drugs, zanubrutinib and sonrotoclax, can shrink chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after earlier treatment. The trial enrolls about 44 adults whose cancer progressed …
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a Faster-Dosed antibody drug paired with lenalidomide help lymphoma that came back after CAR T-Cell therapy?
Disease control Not yet recruitingResearchers are testing a combination of two drugs, epcoritamab and lenalidomide, in adults whose large B-cell lymphoma has come back after CAR T-cell therapy. The trial enrolls about 55 people in France. Participants receive epcoritamab as a shot under the skin using a faster do…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a Three-Drug combo shield stem cell transplant patients from a dangerous immune attack?
Disease control Not yet recruitingThis trial tests a combination of sirolimus, ruxolitinib, and mycophenolate mofetil to prevent acute graft-versus-host disease (aGVHD) in patients receiving a half-matched stem cell transplant. The study focuses on patients with blood cancers or severe aplastic anemia who cannot …
Phase 1/2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a targeted drug boost stem cell transplants for leukemia?
Disease control Not yet recruitingThis phase II trial tests whether adding venetoclax to standard chemotherapy and stem cell transplant, followed by venetoclax maintenance, helps adults with acute myeloid leukemia (AML) stay in remission longer. About 244 participants will receive either venetoclax or a placebo a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Which Second-Line drug works best for axial spondyloarthritis? a trial aims to find out
Disease control Not yet recruitingThis trial tests two different types of drugs—an IL-17 inhibitor (secukinumab) and a JAK inhibitor (upadacitinib)—in people with axial spondyloarthritis who have not improved with a TNF inhibitor. The goal is to see which approach is more effective at reducing disease activity ov…
Phase 4 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a 15-Day wearable sensor keep blood sugar on target?
Disease control Not yet recruitingThis trial tests whether the GX-01S continuous glucose monitoring system helps adults with type 1 or type 2 diabetes improve their blood sugar control. Participants wear the sensor for about 4.5 months, with the first 15 days blinded to establish a baseline, then full access to r…
Sponsor: MicroTech Medical(Hangzhou)Co.,Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug cocktail aims to wipe out Hard-to-Treat leukemia and MDS
Disease control Not yet recruitingThis phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug aims at CD123 to fight Hard-to-Treat blood cancers
Disease control Not yet recruitingResearchers are testing an experimental drug called ORM-1153 in adults whose acute myeloid leukemia (AML) or other blood cancer has returned or stopped responding to treatment. The drug targets CD123, a protein found on the surface of these cancer cells. Participants receive ORM-…
Phase 1 • Sponsor: Orum Therapeutics USA, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody JS203 takes on rituximab in Head-to-Head lymphoma trial
Disease control Not yet recruitingResearchers are testing whether an experimental antibody called JS203, added to gemcitabine and oxaliplatin chemotherapy, helps adults with diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to treatment. The trial compares this combination against the…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Oxygen chamber therapy put to the test for dozens of diseases
Disease control Not yet recruitingThis study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …
Phase 4 • Sponsor: Jay C. Buckey Jr. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a simple bottle help turn the tide on HIV?
Disease control Not yet recruitingThis trial tests whether B-OK bottles, which use beads to visually explain how HIV affects health and how treatment lowers viral load, can help people with HIV stick to their medication. Researchers will roll out the bottles across HIV case management agencies in Philadelphia and…
Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo aims to tailor myeloma treatment to each patient
Disease control Not yet recruitingThis Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consoli…
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a weekly shot bring antibody levels to safety in untreated immune deficiency?
Disease control Not yet recruitingThis trial tests whether TAK-664, an antibody replacement given under the skin, can quickly raise and maintain protective IgG levels in people with primary immunodeficiency who have never received antibody therapy. Participants receive daily doses for 5 days, then a dose on day 8…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can engineered cells beat blood cancers that Won't quit?
Disease control Not yet recruitingThis early-phase trial tests an experimental cell therapy called iMagic Injection in adults with relapsed or refractory blood cancers, specifically B-cell non-Hodgkin lymphoma and multiple myeloma. Participants receive a single infusion of engineered immune cells designed to atta…
Early phase 1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a pill clear psoriasis on hands and feet?
Disease control Not yet recruitingThis trial tests whether an oral medication called zasocitinib (TAK-279) can reduce the redness, thickening, scaling, and painful cracks of palmoplantar psoriasis, a type of psoriasis that affects the palms and soles. Adults with moderate-to-severe non-pustular palmoplantar psori…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a skin cream calm the immune attack after stem cell transplants?
Disease control Not yet recruitingThis pilot study tests whether a cream containing ruxolitinib, a drug that blocks certain immune signals, is safe and helpful for people who develop acute skin graft-versus-host disease (GVHD) after a stem cell transplant. Participants aged 2 to 35 with a malignancy and skin GVHD…
Phase 1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can inhaled cell vesicles soothe damaged lungs in autoimmune disease?
Disease control Not yet recruitingThis early-phase trial tests a nebulized therapy called UC-EVs, derived from human umbilical cord cells, in adults with immune-mediated inflammatory diseases (such as IgG4-related disease or systemic sclerosis) that affect the lungs. Participants inhale the vesicles daily for 7 d…
Early phase 1 • Sponsor: Qiubai Li • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a smart insulin pump tailored for pregnancy protect mothers and babies?
Disease control Not yet recruitingThis trial tests whether an automated insulin delivery system, the DEKA TWIIST pump with Tidepool Loop software, can safely manage glucose levels in pregnant people with type 1 diabetes. The system adjusts insulin automatically and can be set to pregnancy-specific glucose targets…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Head-to-Head: which drug combo tames psoriatic arthritis better?
Disease control Not yet recruitingThis study compares two treatment combinations for adults with psoriatic arthritis who did not get enough relief from methotrexate alone. One group will receive apremilast plus methotrexate, the other adalimumab plus methotrexate. Researchers will measure joint and skin disease a…
Sponsor: Tanta University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for rare immune disorders: upadacitinib trial launches
Disease control Not yet recruitingThis study tests the drug upadacitinib (Rinvoq) in 30 people with rare genetic disorders that overactivate the JAK-STAT immune pathway. The trial has four phases over 12 months, including an open-label phase to find the best dose and a randomized withdrawal phase to compare the d…
Phase 1/2 • Sponsor: Lisa Satter • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New study tests minimally invasive heart valve repair to cut hospital stays
Disease control Not yet recruitingThis study tests whether a minimally invasive heart valve repair procedure (TEER) plus standard medication can reduce hospital readmissions over two years in people with moderate mitral regurgitation that worsens with exertion. About 300 participants will be randomly assigned to …
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a phone app help young adults with HIV stay on track?
Disease control Not yet recruitingThis trial tests whether a smartphone app called PL4Y can help young adults aged 18 to 29 who have HIV stay engaged in their care. For the first 6 months, participants receive standard care. Then they get the app, which sends daily medication reminders, appointment alerts, secure…
Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could a simpler eczema routine boost treatment success?
Disease control Not yet recruitingThis study explores whether giving people with mild-to-moderate eczema a straightforward treatment plan using only Opzelura cream helps them stick to their medication routine. Participants apply the cream twice daily until their skin clears, then as needed. Some participants also…
Phase 4 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a tailored drug combo improve early response in chronic myeloid leukemia?
Disease control Not yet recruitingThis phase II trial tests asciminib as the first treatment for adults newly diagnosed with chronic myeloid leukemia in chronic phase. Patients with unfavorable risk factors also receive dasatinib starting four weeks later. The study measures how many patients achieve a major mole…
Phase 2 • Sponsor: Prof. Dr. med. Andreas Hochhaus • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
A diet tweak may boost platelets in a bleeding disorder
Disease control Not yet recruitingThis trial tests whether adding a selective Mediterranean diet to standard treatment can improve platelet counts and reduce bleeding in adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. Sixty adults aged 18 to 60 with low platelet c…
Sponsor: Assiut University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Stem cells aim to soothe dry eyes in transplant patients
Disease control Not yet recruitingThis study tests whether injecting stem cells into the eye can help people with severe dry eye caused by graft-versus-host disease (GVHD), a complication of bone marrow transplants. The trial will include 30 adults who have not improved with standard treatments. Participants will…
Phase 2 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can one pill tame four autoimmune diseases? a Long-Term trial puts it to the test
Disease control Not yet recruitingThis trial gives deucravacitinib, an oral drug that calms the immune system, to adults with lupus or Sjögren's disease and to children with psoriasis or psoriatic arthritis. Participants join after finishing an earlier study of the same drug, and the goal is to see how safe and t…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new injection calm severe eczema?
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called HXN5003 in healthy volunteers and in people with moderate-to-severe atopic dermatitis, a common form of eczema. The study first gives a single dose to healthy participants to check safety, then gives multiple doses to eczem…
Phase 1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New MS drug trial for kids: could ocrelizumab help?
Disease control Not yet recruitingThis study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New Immunotherapy-Chemo cocktail takes on tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests the safety and best dose of glofitamab, an antibody that helps the immune system attack cancer, when given alongside standard chemotherapy (R-CHOP and R-DHAP) for people with untreated mantle cell lymphoma. Sixteen adults aged 18 to 75 with stage II b…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new injection tame relapsing MS?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called RO7845860, given as an injection under the skin, in people with relapsing multiple sclerosis (MS). The main goals are to check the drug's safety, how the body handles it, and its effects on immune cells. The study w…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThis trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…
Phase 1/2 • Sponsor: Servier • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New trial aims to find best treatment for lung complication in rheumatoid arthritis
Disease control Not yet recruitingThis 52-week study will compare three drugs—tocilizumab, telitacicept, and methotrexate—in 204 people with rheumatoid arthritis who also have interstitial lung disease. The main goal is to see which drug best improves lung function. Participants will continue their usual arthriti…
Phase 4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new oral drug tame psoriasis? early safety trial begins
Disease control Not yet recruitingThis Phase 1 trial tests a single oral dose of HRS-4139, an experimental drug for psoriasis, in healthy adults aged 18 to 55. Researchers measure how the body absorbs and processes the drug, and watch for any side effects. The goal is to establish a safe dose for future studies i…
Phase 1 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New cocktail aims to tame myeloma without transplant
Disease control Not yet recruitingThis study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control …
Phase 1/2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could vitamin c help protect the gut in transplant patients?
Disease control Not yet recruitingThis early-phase trial tests whether adding vitamin C to standard steroid treatment helps people with gastrointestinal graft-versus-host disease (GVHD), a serious complication after a donor stem cell transplant. About 35 participants aged 5 and older will receive vitamin C plus s…
Early phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to outsmart aggressive myeloma
Disease control Not yet recruitingThis phase 2 trial tests whether giving two bispecific antibodies (teclistamab and talquetamab) in sequence, along with other drugs, can improve survival in 50 people with high-risk multiple myeloma. Some participants may also receive a stem cell transplant if cancer cells remain…
Phase 2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can probiotic spores tame Crohn's and colitis Flare-Ups?
Disease control Not yet recruitingThis trial tests whether adding Bacillus probiotic spores to standard treatment can help people with Crohn's disease or ulcerative colitis. Researchers will give 150 adults either a placebo or one of two probiotic formulas for 30 days, alongside their usual care. The goal is to s…
Sponsor: Anabio R&D • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could CAR-T cells tame autoimmune diseases? early safety trial launches
Disease control Not yet recruitingThis early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma that haven't improved with standard treatments. Only 6 adults aged 18-…
Phase 1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to replace chemo for lymphoma patients
Disease control Not yet recruitingThis phase 2 trial is testing a combination of three drugs (polatuzumab vedotin, glofitamab, and tafasitamab) as a first-line treatment for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. The goal is to see if this chemo-free approach can shrink tumors an…
Phase 2 • Sponsor: Brown University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new pill tame inflammatory bowel disease?
Disease control Not yet recruitingThis phase 1 trial tests the safety and tolerability of LMT503, an oral drug intended for inflammatory bowel disease, in healthy adults aged 18 to 65. Participants receive either LMT503 or a placebo in single or multiple ascending doses, with some also checking how food affects t…
Phase 1 • Sponsor: Lmito Therapeutics Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Off-the-Shelf CAR t cells take on tough blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new 'universal' CAR T cell therapy (4SCAR19U) for people with B cell cancers that have come back or not responded to treatment. The therapy uses donor-derived immune cells engineered to target CD19 on cancer cells. The study aims to check safety and…
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug outsmart a rare blood cancer?
Disease control Not yet recruitingThis phase 2 trial tests whether teclistamab can treat Waldenstrom's macroglobulinemia, a rare blood cancer, in people whose disease has returned or not responded to prior therapy. Participants receive teclistamab as a subcutaneous injection for up to 9 cycles. Researchers measur…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a withdrawn myeloma drug make a comeback with a gentler schedule?
Disease control Not yet recruitingThis study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, b…
Phase 2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can engineered immune cells tame a stubborn autoimmune disease?
Disease control Not yet recruitingThis trial tests a single infusion of BCT301, a cell therapy made from stem cells that are engineered to target the immune system, in 6 adults with IgG4-related disease that has not improved with standard treatment. The main goal is to check whether the infusion is safe and toler…
Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Same-Day HIV treatment: a new weapon against stigma?
Disease control Not yet recruitingResearchers in Peru are testing whether starting antiretroviral therapy on the same day as diagnosis can reduce the stigma that people with HIV face. The study involves developing a same-day treatment protocol with input from HIV experts, then piloting it with patients and their …
Sponsor: Yale University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Eye surgery breakthrough? tiny trial tests humira injection during corneal implant
Disease control Not yet recruitingThis early-stage trial will test whether injecting adalimumab (Humira) into the eye during Boston KPro surgery is safe for 8 patients with severe corneal damage. The study focuses on side effects and tolerability, not yet on how well it works. It is for people who have run out of…
Phase 1 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Real-World study reveal the staying power of guselkumab?
Disease control Not yet recruitingThis observational study tracks how long patients with moderate-to-severe Crohn's disease or ulcerative colitis continue taking guselkumab, a biologic treatment, in everyday clinical practice. Researchers will measure time until treatment discontinuation and early responses like …
Sponsor: Janssen Sciences Ireland UC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Goat milk ladder may offer a new route to milk tolerance in allergic children
Disease control Not yet recruitingThis trial tests whether a four-step ladder made with goat milk formula helps children aged 1 to 5 with cow's milk allergy build tolerance to milk better than the standard cow's milk ladder. Both ladders start with baked goods and progress to plain milk over 12 weeks, with each s…
Sponsor: Medical University of Warsaw • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a potato starch shake off Drug-Resistant gut bacteria?
Disease control Not yet recruitingThis trial tests whether a dietary fiber called resistant potato starch can reduce the amount of drug-resistant bacteria living in the gut. The study enrolls Veterans who carry these bacteria without symptoms, and half will take the starch daily while the other half takes a place…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
A new approach to protect young hearts from lupus complications
Disease control Not yet recruitingThis study tests whether adding a health navigator to pediatric lupus care teams helps more children receive recommended blood pressure checks and treatments. The trial involves 16 pediatric lupus clinics, which will be randomly assigned to different implementation strategies. Re…
Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for myeloma patients: could ramantamig plus daratumumab outperform standard care?
Disease control Not yet recruitingThis phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from p…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a Four-Drug combo tame Ultra-High-Risk myeloma?
Disease control Not yet recruitingThis phase 2 trial tests whether adding elranatamab to a standard three-drug regimen can improve outcomes for people newly diagnosed with ultra-high-risk multiple myeloma. Researchers will give 15 participants elranatamab, isatuximab, bortezomib, and lenalidomide, and measure how…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can engineered immune cells calm autoimmune blood disorders?
Disease control Not yet recruitingThis phase 1 trial tests a one-time infusion of AZD0120, a CAR-T cell therapy that targets CD19 and BCMA, in people with relapsed or refractory immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). Participants receive a short course of bendamustine before th…
Phase 1 • Sponsor: Saurabh Dahiya • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can pressurized oxygen heal Crohn's fistulas when drugs fail?
Disease control Not yet recruitingThis study tests whether hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — can help heal perianal fistulas in people with Crohn's disease who haven't improved with standard treatments. Participants will either receive HBOT or continue with conven…
Phase 1/2 • Sponsor: University of British Columbia • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Two-Drug chemo combo outsmart resistant tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo targets Tough-to-Treat myeloma
Disease control Not yet recruitingThis phase 2 trial is testing a new drug called CM336, given alongside standard therapy, for people with high-risk multiple myeloma. The study will include 46 adults aged 18 to 75. The main goal is to see if the combination can reduce cancer cells to very low levels (MRD negativi…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can cancer care include heart checks? a pilot study puts two models to the test
Disease control Not yet recruitingThis pilot study explores whether a structured heart-health assessment can be done successfully and on time for adults with multiple myeloma who are starting a new line of treatment. Participants will be assigned by chance to receive the assessment either from a clinician embedde…
Sponsor: University of Vermont Medical Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new pill outperform standard care for ulcerative colitis?
Disease control Not yet recruitingThis trial compares two oral medications for active ulcerative colitis, a chronic inflammatory bowel disease causing diarrhea, bleeding, and pain. About 320 Chinese adults will be randomly assigned to take either etrasimod, a newer drug that blocks immune cells from entering the …
Phase 4 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can engineered immune cells tame autoimmune diseases?
Disease control Not yet recruitingThis trial is testing an experimental therapy called CTA313, which uses engineered immune cells (CAR T cells) to potentially reset the immune system in people with active autoimmune diseases. The study will include adults aged 18 to 75 with systemic lupus erythematosus, progressi…
Phase 1 • Sponsor: Imviva Bio • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new injection quiet severe eczema?
Disease control Not yet recruitingThis Phase 3 trial is testing whether an experimental biologic called tilrekimig can reduce the severity of moderate-to-severe atopic dermatitis (eczema) in people aged 12 and older. Participants will receive either tilrekimig, an existing treatment (dupilumab), or a placebo for …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a drug plus surgery heal Crohn's fistulas for good?
Disease control Not yet recruitingThis trial is testing whether combining the drug mirikizumab with a surgical procedure can help heal perianal fistulas in people with Crohn's disease. Participants will receive the drug through infusions and injections, along with two surgical steps to clean and close the fistula…
Phase 4 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a new shoulder implant restore arm function where others fail?
Disease control Not yet recruitingThis study is following people who receive a Tornier Perform™ Reversed MonoPost shoulder replacement to see how well it works and how safe it is. The implant is designed for patients with severe shoulder damage, such as from arthritis, fractures, or failed previous surgeries. Res…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
A pill after transplant: new hope to stop t-cell cancer relapse
Disease control Not yet recruitingThis trial tests whether taking chidamide, an oral drug, after a stem cell transplant can lower the chance of the cancer coming back in people with high-risk T-cell acute lymphoblastic leukemia or lymphoma. Participants are randomly assigned to receive chidamide for up to 24 mont…
Phase 3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could a 7-Day antibiotic course replace 3 weeks for silent STI?
Disease control Not yet recruitingThis trial tests whether a 7-day course of doxycycline can effectively cure asymptomatic anal lymphogranuloma venereum (LGV), a sexually transmitted infection caused by Chlamydia trachomatis. Currently, treatment lasts 21 days, but recent studies suggest a shorter course may work…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could a painless microneedle pad ease Raynaud's in scleroderma?
Disease control Not yet recruitingThis Phase 3 trial is testing whether a microneedle pad delivering botulinum toxin A can improve symptoms of Raynaud's phenomenon and digital ulcers in people with systemic sclerosis. The study compares the microneedle treatment to a placebo, measuring changes in finger temperatu…
Phase 3 • Sponsor: Khon Kaen University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a common drug boost Chemo's power against Hard-to-Treat leukemia?
Disease control Not yet recruitingThis trial is testing whether adding hydroxyurea to a standard chemotherapy combination can improve outcomes for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The study is conducted in two parts: first to find the safest dose of hydroxy…
Phase 1/2 • Sponsor: Christer C Nilsson • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a blood pressure pill slow MS disability?
Disease control Not yet recruitingThis phase 2 trial tests whether indapamide, a common diuretic, can slow the worsening of walking ability in people with progressive multiple sclerosis (MS). Participants take one tablet daily for 12 months, with walking speed measured regularly. The study aims to see if the drug…
Phase 2 • Sponsor: Eva M.M. Strijbis • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can an immune booster outsmart brain lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding an immunotherapy drug called penpulimab to a standard chemotherapy regimen can help people with primary central nervous system lymphoma, a rare type of brain cancer. Participants, who have not yet received treatment, are randomly assigned to r…
Sponsor: WEI XU • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug calm the Gut's overactive immune response in Crohn's?
Disease control Not yet recruitingThis phase 2 trial is testing whether an investigational drug called SL-325 can help adults with moderate to severe Crohn's disease. The study will compare SL-325 against a placebo to see if it reduces gut inflammation and improves symptoms. Participants will receive the treatmen…
Phase 2 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new injection calm Sjogren's nerve damage?
Disease control Not yet recruitingThis trial tests whether an experimental drug called efgartigimod can reduce nerve damage and pain in adults with Sjogren's disease. Participants will receive either the drug or a placebo as a subcutaneous injection. The study measures changes in neuropathy symptoms and quality o…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant myeloma?
Disease control Not yet recruitingThis phase II trial is testing whether combining teclistamab, an antibody that helps immune cells attack myeloma cells, with pomalidomide, a drug that slows cancer growth, can control multiple myeloma in people whose disease has returned or stopped responding after 1-3 prior trea…
Phase 2 • Sponsor: Odense University Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a psychedelic help break meth addiction in people with HIV?
Disease control Not yet recruitingThis trial explores whether a single dose of psilocybin, combined with motivational support therapy, can help people with HIV who have moderate-to-severe methamphetamine use disorder reduce or stop their meth use. Participants will be randomly assigned to receive either a higher …
Phase 2 • Sponsor: Nicky Mehtani, MD, MPH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Spanish-language pump training aims to close diabetes tech gap for latino youth
Disease control Not yet recruitingThis trial tests whether a culturally tailored, Spanish-language onboarding and support program helps Latino youth aged 10–20 with type 1 diabetes adopt and consistently use the Medtronic MiniMed 780G automated insulin delivery system. Participants receive one-on-one nutrition su…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can Open-Source insulin systems match commercial ones without meal announcements?
Disease control Not yet recruitingThis trial tests whether open-source automated insulin delivery (AID) systems can control blood sugar as well as commercial systems in adults with type 1 diabetes, even when meals are not announced. Participants will use both types of systems for four weeks each, with a focus on …
Sponsor: Institut de Recherches Cliniques de Montreal • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a diabetes drug curb chronic Pouch-Related bathroom trips?
Disease control Not yet recruitingThis trial tests whether tirzepatide (Zepbound) can reduce daily bowel frequency in adults with an ileal pouch-anal anastomosis (IPAA) who have chronic high bowel frequency despite standard anti-diarrheal therapy. Participants will be assigned to receive tirzepatide or standard c…
Phase 4 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for young adults with CML: asciminib under Real-World scrutiny
Disease control Not yet recruitingThis study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart resistant leukemia?
Disease control Not yet recruitingThis trial tests whether adding gilteritinib to the standard drugs azacitidine and venetoclax can help adults with a type of acute myeloid leukemia (AML) that has returned or stopped responding to prior treatment. Participants receive the three-drug combination in repeated 28-day…
Phase 2 • Sponsor: Florian Kuchenbauer • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
Disease control Not yet recruitingThis phase III trial is testing whether regular antibody infusions (immunoglobulin replacement therapy) can prevent infections better than standard antibiotic prophylaxis in people who have received CAR-T cell therapy for B-cell acute lymphoblastic leukemia or B-cell lymphoma. CA…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
Disease control Not yet recruitingThis phase 2 trial is testing whether an oral drug called flonoltinib maleate can help adults with myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen and severe symptoms. The study compares three different daily doses (50 mg, 75 mg, and 100 mg) to see…
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a probiotic keep ulcerative colitis in check?
Disease control Not yet recruitingThis trial is testing whether a probiotic supplement called Colipral, which contains a specific strain of E. coli bacteria, can improve gut health in people with ulcerative colitis who are in remission but still have digestive issues. Participants will take either the supplement …
Sponsor: University of Padova • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new antibody help lupus patients ditch steroids?
Disease control Not yet recruitingThis trial is testing whether anifrolumab, an experimental antibody, can help Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE) achieve remission. Participants receive anifrolumab infusions over 52 weeks alongside standard care, with a focus on safely redu…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted antibody calm severe eczema?
Disease control Not yet recruitingThis first-in-human trial evaluates BYN-001, an antibody designed to block IL-25, a protein linked to atopic dermatitis (eczema). The study first tests the drug in healthy volunteers to assess safety and how it moves through the body, then in people with moderate to severe eczema…
Phase 1 • Sponsor: Bionyra Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
A drug after transplant may stop scleroderma from coming back
Disease control Not yet recruitingThis pilot trial tests whether giving the immunosuppressant drug mycophenolate mofetil (MMF) for six months after a stem cell transplant can prevent systemic sclerosis from relapsing. Six adults with scleroderma who are undergoing a stem cell transplant will take MMF starting 90 …
Phase 2 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
Disease control Not yet recruitingThis phase 2 trial is testing an investigational drug called QLS4131 in people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs and cause damage. QLS4131 is a trispecific antibody designed to target and eliminate the plasma cells produci…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted drug shrink Hard-to-Treat thymic tumors?
Disease control Not yet recruitingThis phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
Disease control Not yet recruitingThis trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at le…
Phase 2 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug beat radiation for early-stage lymphoma?
Disease control Not yet recruitingThis phase 3 trial compares the experimental drug surovatamig with standard involved-site radiotherapy (with or without rituximab) in people with limited-stage follicular lymphoma. The goal is to see if surovatamig can produce deeper, longer-lasting responses and reduce the chanc…
Phase 3 • Sponsor: Australasian Leukaemia and Lymphoma Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new biologic tame ulcerative colitis?
Disease control Not yet recruitingThis early trial is testing an experimental biologic drug called aletekitug in adults with moderate to severe ulcerative colitis. The main goal is to see if the drug is safe and tolerable when given repeatedly. Researchers will monitor side effects and changes in lab tests, vital…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a pill outperform biologics for severe eczema?
Disease control Not yet recruitingThis study looks at how well upadacitinib, a daily pill, works compared to biologic injections for people with moderate-to-severe atopic dermatitis (eczema). The goal is to see if more patients can reach a state of minimal disease activity, meaning nearly clear skin and little to…
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a simple injection replace an IV for this myeloma drug?
Disease control Not yet recruitingThis trial is testing whether belantamab, a drug used for multiple myeloma, can be given as a quick injection under the skin instead of a slow drip into a vein. About 22 adults with multiple myeloma who are already on standard maintenance therapy will receive both forms in a cros…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a dual immunotherapy erase hidden myeloma cells?
Disease control Not yet recruitingThis phase 3 trial tests whether combining two immunotherapies, teclistamab and talquetamab, can eliminate residual cancer cells in multiple myeloma patients who have undergone a stem cell transplant. Participants with detectable minimal residual disease (MRD) are randomly assign…
Phase 3 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can umbilical cord stem cells help repair spinal cord injuries?
Disease control Not yet recruitingThis trial is testing whether a single injection of stem cells from umbilical cord tissue, given into the spinal fluid, is safe and tolerable for people who have had a traumatic spinal cord injury within the past ten years. The study will monitor participants for side effects and…
Early phase 1 • Sponsor: Cell Therapy LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a higher dose of upadacitinib rescue ulcerative colitis patients when standard treatment fails?
Disease control Not yet recruitingThis study tests whether a temporary higher dose of upadacitinib (45 mg daily) can bring ulcerative colitis back under control in adults whose disease flared up while on the standard 30 mg maintenance dose. Participants receive the higher dose for 8 to 16 weeks, then may step dow…
Phase 4 • Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart High-Risk CLL?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding a new immune-boosting drug, epcoritamab, to two existing targeted therapies (ibrutinib and venetoclax) can improve outcomes for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have TP53 …
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can Real-Time MRI make radiation safer for Ultra-Central lung tumors?
Disease control Not yet recruitingThis trial tests whether MRI-guided stereotactic body radiotherapy (SBRT) can safely treat ultra-central lung tumors—growths located near the windpipe and major airways. Using an MR-LINAC machine, doctors can adjust the radiation beam in real time as the patient breathes, potenti…
Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Personalizing leukemia care for seniors: a fitness-based treatment strategy put to the test
Disease control Not yet recruitingThis phase 2 trial tests whether using a comprehensive geriatric assessment to guide treatment selection can reduce side effects and improve outcomes in adults aged 60 and older with newly diagnosed acute myeloid leukemia. Participants are classified as fit, vulnerable, or frail,…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an online brain workout sharpen thinking in multiple sclerosis?
Disease control Not yet recruitingThis trial tests whether a year-long, home-based cognitive training program can improve memory, attention, and emotional understanding in people with multiple sclerosis. Participants use the COGWEB platform plus exercises for recognizing facial expressions, with most sessions don…
Sponsor: Sonia Batista • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
Disease control Not yet recruitingThis trial investigates whether revumenib, a menin inhibitor, can safely and effectively treat myelofibrosis, a type of bone marrow cancer. The study first tests revumenib alone in patients who have already tried a JAK inhibitor, then tests it in combination with a JAK inhibitor.…
Phase 1/2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
Disease control Not yet recruitingThis phase 1 trial is testing an experimental drug called ATG-201 in adults with systemic lupus erythematosus, systemic sclerosis, or Sjögren's disease. ATG-201 is designed to bind to specific proteins on immune cells, potentially quieting the overactive immune response that driv…
Phase 1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Ancient herbs meet modern medicine: can Curcumin-QingDai tame UC?
Disease control Not yet recruitingThis study tests whether adding a combination of curcumin (from turmeric) and QingDai (a traditional Chinese herb) to standard vedolizumab treatment can help people with moderate to severe ulcerative colitis reach remission. About 160 adults will receive either the herbal combo o…
Phase 4 • Sponsor: Ryan C Ungaro • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a targeted pill tame a rare immune disease?
Disease control Not yet recruitingThis phase 2 trial is testing whether the experimental drug luvometinib, taken alone or with the chemotherapy drug cytarabine, can control Langerhans cell histiocytosis—a rare disease where immune cells build up and damage tissues. People aged 10 and older who need systemic treat…
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a cancer drug reboot the immune system in chronic fatigue syndrome?
Disease control Not yet recruitingThis trial tests whether inebilizumab, an antibody that wipes out certain immune cells called B cells, can improve physical function in adults with ME/CFS that started after an infection. Participants receive three infusions over six months, and the study measures changes in mobi…
Phase 2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a burst of radiation make CAR t-cells fight cancer harder?
Disease control Not yet recruitingThis trial tests whether adding a small dose of total body radiation to standard CAR T-cell therapy can help the immune cells grow stronger and last longer in the body. It enrolls adults with relapsed or hard-to-treat diffuse large B-cell lymphoma or multiple myeloma who are alre…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental drug targets bone marrow failure
Disease control Not yet recruitingThis study tests an experimental drug called dibotatug (DR-01) in adults with bone marrow failure syndromes, including severe aplastic anemia. The goal is to see if the drug is safe and can improve blood cell counts. Participants receive dibotatug by IV infusion, and researchers …
Phase 1/2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a spring-powered injector make cancer drug delivery smoother for patients and nurses?
Disease control Not yet recruitingThis trial tests whether a mechanical, spring-driven device called FreedomEDGE® can safely and effectively deliver daratumumab, a standard treatment for multiple myeloma and amyloidosis. Currently, nurses give these injections by hand, which can be physically demanding. About 100…
Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a single drug calm lupus kidney disease without a cocktail of meds?
Disease control Not yet recruitingThis phase II trial tests whether obinutuzumab, a B-cell targeting antibody, can alone achieve complete kidney response in people with pure class V lupus nephritis—a form of lupus kidney disease with no approved treatments. Participants receive up to four infusions over seven mon…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a community health worker program save lives in advanced HIV?
Disease control Not yet recruitingThis trial tests whether a package of support from a community health worker can help adults hospitalized with advanced HIV in Lusaka, Zambia, stay in care and survive longer. Participants are randomly assigned to receive the ARC intervention or standard care and are followed for…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a One-Two drug punch beat back Hard-to-Treat myeloma?
Disease control Not yet recruitingThis early-phase trial is testing whether combining two targeted drugs—talquetamab and belantamab mafodotin—can safely control multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults with myeloma who have already tried at least one p…
Phase 1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
A steroid-sparing strategy for IgG4-related disease: lenalidomide put to the test
Disease control Not yet recruitingThis phase III trial tests whether lenalidomide, an immune-modulating drug, can prevent disease flares in people with IgG4-related disease who are in remission. Participants receive either lenalidomide or a placebo for 52 weeks while tapering off steroids. The goal is to see if l…
Phase 3 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can ulcerative colitis patients in remission ditch their daily pill?
Disease control Not yet recruitingThis trial asks whether adults with ulcerative colitis who are in deep remission can safely stop taking their JAK inhibitor medication (tofacitinib, upadacitinib, or filgotinib) instead of continuing daily maintenance therapy. Half of the 224 participants will stop treatment and …
Phase 4 • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
Disease control Not yet recruitingThis study tests whether an artificial intelligence (AI) system can help choose the best combination of drugs for older patients newly diagnosed with large B-cell lymphoma. Participants are first treated with a standard two-drug regimen (ZR2), then those at intermediate or high r…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New combo therapy aims to boost remission in Hard-to-Treat lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Fewer radiation sessions may be just as effective for thymic tumors after surgery
Disease control Not yet recruitingThis clinical trial is testing a shorter, more intense course of radiation therapy (called hypofractionated radiotherapy) for people who have had surgery for thymic epithelial tumors, including thymoma and thymic carcinoma. The goal is to see if this approach can keep the tumor f…
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can screening for social needs improve diabetes care for kids?
Disease control Not yet recruitingThis study tests a program where social workers screen families of youth with type 1 diabetes for social challenges like food insecurity, then connect them to community resources. The goal is to see if this approach is practical and acceptable, and whether it can improve diabetes…
Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Real-World study tests Once-Daily pill for ulcerative colitis in chinese adults
Disease control Not yet recruitingThis study looks at how the oral medication etrasimod works for Chinese adults with active ulcerative colitis (UC) in real-world settings. About 500 participants will take etrasimod as part of their routine care and be followed for at least 52 weeks. Researchers will track change…
Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Herbal formula may help HIV patients whose immune systems Don't fully recover
Disease control Not yet recruitingThis study tests whether adding Qiling Yiqi tablets, a Chinese herbal medicine, to standard HIV therapy can improve immune function in people whose CD4 counts remain low despite successful viral suppression. The trial involves 240 adults with HIV who have been on antiretroviral t…
Sponsor: Beijing University of Chinese Medicine • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gene therapy aims to tame rare immune disorder
Disease control Not yet recruitingThis trial tests a new gene therapy called FOXP3-T4 for people with IPEX syndrome, a rare genetic condition that causes severe immune problems. The therapy involves taking a patient's own immune cells, modifying them in the lab to work better, and giving them back via a single in…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Herbal granules aim to revive immune system in HIV patients
Disease control Not yet recruitingThis study tests whether adding Fuyang Jiedu Granules, a traditional Chinese herbal mixture, to standard antiretroviral therapy can improve immune function in people with HIV who have persistently low CD4 counts despite viral suppression. The trial includes 240 adults aged 18–60 …
Sponsor: Beijing University of Chinese Medicine • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
AR goggles could help surgeons spot cancer cells left behind during breast cancer surgery
Disease control Not yet recruitingThis trial tests whether special augmented-reality goggles can help surgeons find lymph nodes that may be missed during breast cancer surgery. The goggles show a fluorescent dye that collects in lymph nodes, allowing the surgeon to re-examine the area after the planned removal is…
Sponsor: Ss. Cyril and Methodius University of Skopje • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Single-Dose gene therapy aims to reprogram immune cells against tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a single injection of PID23, a gene therapy that instructs a patient's own immune cells to attack leukemia cells. It targets three markers (CD19, BCMA, and CD70) on cancer cells. The study enrolls up to 18 people aged 3 to 75 with relapsed or refracto…
Early phase 1 • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Continued anifrolumab treatment studied for lupus and related diseases
Disease control Not yet recruitingThis study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a safer start to a key CLL drug be possible? new study reexamines the risk
Disease control Not yet recruitingThis study looks at people with chronic lymphocytic leukemia (CLL) who are about to start treatment with venetoclax, a targeted therapy. Doctors want to see if starting with other drugs first lowers the risk of tumor lysis syndrome, a dangerous side effect where cancer cells brea…
Sponsor: Private Hospital of Confluent, France • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a smartphone app help teens tame type 1 diabetes?
Disease control Not yet recruitingThis study tests whether a mobile app that provides structured diabetes education can help adolescents with type 1 diabetes improve their blood sugar control, confidence, and self-care habits. Participants aged 10 to 19 with type 1 diabetes and an HbA1c of 7% or higher will use t…
Sponsor: Shifa Tameer-e-Millat University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Gene-Guided Chemo-Free strategy targets AL amyloidosis
Disease control Not yet recruitingThis study tests two chemotherapy-free treatments for people newly diagnosed with AL amyloidosis, a rare blood disorder. The choice of treatment depends on whether the patient has a specific genetic change called t(11;14). Those with t(11;14) receive a daily pill called sonrotocl…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill aims to tame rheumatoid arthritis inflammation
Disease control Not yet recruitingThis study tests an experimental oral drug called JAB-8263 in adults with active rheumatoid arthritis. The goal is to see if it is safe and can reduce joint inflammation and pain. Participants take the drug or a placebo every other day for 28 days. The trial is small and early-st…
Phase 2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill targets immune signals in rare lymphomas
Disease control Not yet recruitingThis pilot study tests an oral drug called golidocitinib in people with two rare blood cancers: mycosis fungoides/Sézary syndrome (a type of skin lymphoma) and T-cell large granular lymphocytic leukemia. The drug blocks a protein called JAK1, which is involved in cancer cell grow…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Two-Drug sequence aims to clear CLL cells and let patients stop treatment
Disease control Not yet recruitingThis phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this seque…
Phase 2 • Sponsor: Yi Shuhua • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Herbal mix and cancer drug join forces to fight fluid in lungs
Disease control Not yet recruitingThis study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…
Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a drug calm the immune storm in severe abdominal infections?
Disease control Not yet recruitingThis study tests whether ulinastatin, a drug that reduces inflammation, can help patients with severe abdominal infections. The infection often causes the immune system to overreact, leading to organ failure and high risk of death. Researchers will give patients either a low or h…
Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New antibody drug aims to save Insulin-Making cells in type 1 diabetes
Disease control Not yet recruitingThis Phase 3 study tests SAB-142, an antibody that targets immune cells, in 108 people aged 5 to 40 with type 1 diabetes. The goal is to see if it can preserve the body's ability to produce insulin over 12 months. Participants receive either the drug or a placebo alongside standa…
Phase 3 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug cocktail aims to deepen remission in multiple myeloma patients
Disease control Not yet recruitingThis Phase 3 trial tests whether adding the drug Teclistamab to a standard treatment regimen (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) improves outcomes for newly diagnosed multiple myeloma patients eligible for stem cell transplant. About 399 adults aged 18-70 will …
Phase 3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New eye drops aim to calm Sjögren's dry eye by blocking inflammation
Disease control Not yet recruitingThis phase 2 trial tests whether eye drops containing infliximab, a drug that blocks a key inflammatory protein, can safely improve severe dry eye in people with Sjögren's syndrome. 38 adults will receive either the active drops or a steroid drop for 6 weeks. The study measures s…
Phase 2 • Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Crohn's blockage showdown: drugs or surgery for better quality of life?
Disease control Not yet recruitingThis trial compares two approaches for people with Crohn's disease who have a narrowed section of the small bowel causing symptoms. One group receives a combination of two drugs (azathioprine and infliximab), while the other group undergoes surgery to remove the narrowed segment.…
Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, glofitamab and selinexor, in 30 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. The goal is to see how many patients achieve a complete response (cancer dis…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Zapping kidney nerves: a Needle-Free hope for high blood pressure?
Disease control Not yet recruitingThis pilot study tests a new device that uses radiofrequency energy to calm overactive kidney nerves, which can drive high blood pressure. Twenty adults with untreated mild hypertension will either get the real procedure or a sham (fake) one. The main goal is to see if the real t…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with ITP: drug combo aims to control bleeding
Disease control Not yet recruitingThis phase 2 trial tests whether adding ianalumab to eltrombopag helps children aged 5 to 17 with primary immune thrombocytopenia (ITP) who didn't improve after steroids. The goal is to see if the combination can raise platelet counts and prevent bleeding. About 36 children will …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingThis trial tests a one-time treatment called CAR-T cell therapy for people with systemic lupus erythematosus (lupus) that hasn't improved with standard medications. The therapy uses a patient's own immune cells, which are modified in a lab to find and destroy the B cells that dri…
Phase 1/2 • Sponsor: University of Sao Paulo • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New uganda trial tackles alcohol and HIV care for men with pregnant partners
Disease control Not yet recruitingThis pilot study tests a program called Kisoboka Amaka for men living with HIV who drink heavily and have pregnant partners. The program combines counseling, financial training, and mobile savings to help men drink less and take their HIV medication consistently. Researchers will…
Sponsor: San Diego State University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a maintenance drug keep lymphoma at bay? new trial aims to find out.
Disease control Not yet recruitingThis phase 2 trial tests whether giving rituximab maintenance therapy after initial treatment with rituximab and lenalidomide (R2) can improve outcomes for people with untreated marginal zone lymphoma. About 144 patients who respond to R2 will be randomly assigned to receive ritu…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to lock in remission for rare lymphoma
Disease control Not yet recruitingThis study tests whether the drug elranatamab can help keep plasmablastic lymphoma, a rare and aggressive blood cancer, from returning after initial chemotherapy. About 17 adults with or without HIV who have already responded to first treatment will receive elranatamab injections…
Phase 2/3 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot plus light therapy aims to restore skin color in vitiligo
Disease control Not yet recruitingThis study tests a new medicine called GR2301, given as shots under the skin, together with light therapy for people with vitiligo (a condition that causes white patches on the skin). The trial has two parts: first, finding the right dose, then testing how well it works. About 11…
Phase 1/2 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
AI-Powered tool aims to sharpen MS treatment choices
Disease control Not yet recruitingThis study tests a computer program called PRIMUS that helps neurologists choose treatments for people with relapsing-remitting multiple sclerosis (MS). The tool uses data from past patients to predict how the disease might progress under different therapies. Doctors in some clin…
Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Blood clot risk in rare disease: could a higher dose of clopidogrel offer better protection?
Disease control Not yet recruitingThis study looks at whether a higher dose of the blood thinner clopidogrel works better for people with essential thrombocythemia (ET), a rare blood disorder that raises the risk of dangerous blood clots. The standard dose may not work well for many ET patients, so researchers wi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to tame transplant complication
Disease control Not yet recruitingThis phase 2 trial tests a combination of two oral drugs, ruxolitinib and belumosudil, for chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. cGvHD is a serious condition where donor immune cells attack the patient's body after a stem cell transplant. T…
Phase 2 • Sponsor: Dennis Kim • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Gentle exercise with cuffs may boost muscle in MS patients
Disease control Not yet recruitingThis study tests whether adding blood flow restriction cuffs to light leg exercises can help people with relapsing-remitting multiple sclerosis build bigger, stronger thigh muscles. Thirty participants will do the same exercise twice a week for 8 weeks, but some will have the cuf…
Sponsor: Hanifi Bal • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for teens with rare nerve disease: drug trial launches
Disease control Not yet recruitingThis study tests a new medicine called empasiprubart in teenagers aged 12 to 17 who have a rare nerve disease called CIDP. The goal is to find the right dose and see if the drug is safe and helps control the disease. Participants will receive the drug for about 27 months and be f…
Phase 2/3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Video Game-Style education could help kids control diabetes
Disease control Not yet recruitingThis study tests whether an interactive educational video, added to standard diabetes education, helps children aged 8 to 14 with type 1 diabetes improve their blood sugar control. The video lets kids make decisions in everyday situations and see the results. Researchers will mea…
Sponsor: G. d'Annunzio University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to outsmart leukemia with less poison
Disease control Not yet recruitingThis phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamici…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Ancient gut therapy takes on allergies in new clinical trial
Disease control Not yet recruitingThis study tests whether an Ayurvedic treatment that targets digestion and gut health can reduce allergy symptoms and immune markers in people with allergic rhinitis (hay fever). 104 adults aged 18-40 with confirmed allergies will receive either the Ayurvedic treatment plus stand…
Sponsor: Amrita Vishwa Vidyapeetham • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Your phone as a stethoscope: can an app spot hidden heart valve disease?
Diagnosis Not yet recruitingResearchers are testing whether a smartphone app called Stethophone can help primary care doctors find moderate or severe aortic stenosis in adults aged 70 and older. The app turns a phone into a digital stethoscope and analyzes heart sounds for murmurs that may signal the condit…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Breath test aims to classify leukaemia in hours, not days
Diagnosis Not yet recruitingDoctors often wait days for genetic tests to classify acute myeloid leukaemia (AML) and guide treatment. This trial tests whether breath analysis can detect metabolic products from leukaemia and classify the disease faster. Participants give breath samples and extra blood tests d…
Sponsor: Jeremy Deuel • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Smartphone app aims to catch rheumatoid arthritis before it takes hold
Diagnosis Not yet recruitingResearchers are testing whether a smartphone app called DETECTRA can help doctors diagnose rheumatoid arthritis earlier in adults who have joint symptoms and a positive ACPA blood test. Participants are randomly assigned to receive standard care alone or standard care plus the ap…
Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Inhaled xenon gas could reveal hidden lung vessel disease without catheter
Diagnosis Not yet recruitingResearchers are testing a noninvasive MRI technique that uses inhaled hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis. The study includes about 51 participants, including healthy volunteers…
Phase 2 • Sponsor: Bastiaan Driehuys • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Cheap blood test could flag diabetic kidney damage before it strikes
Diagnosis Not yet recruitingResearchers at Assiut University are studying whether two types of routine blood measurements can help predict how quickly kidney disease worsens in people with diabetes. The first is the Triglyceride-Glucose index, a calculation from standard cholesterol and blood sugar tests. T…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
AI learns to measure bowel inflammation from ultrasound
Diagnosis Not yet recruitingResearchers at the University of British Columbia are collecting intestinal ultrasound images from adults, including healthy people and those with inflammatory bowel disease such as Crohn disease or ulcerative colitis. The goal is to build a computer program that can measure bowe…
Sponsor: University of British Columbia • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
Can a driving simulator reveal hidden driving risks in Parkinson's and MS?
Diagnosis Not yet recruitingResearchers at University Hospital Olomouc are studying whether a standardized driving simulator can detect differences in driving performance among people with Parkinson's disease, people with multiple sclerosis, and healthy drivers. About 100 participants with a valid driver's …
Sponsor: University Hospital Olomouc • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
A simple stool test might replace scopes for kids with gut issues
Diagnosis Not yet recruitingResearchers at Assiut University are testing whether a stool test for calprotectin, a protein linked to inflammation, can accurately detect gut inflammation in children with chronic digestive symptoms. The study will compare stool test results with findings from endoscopy and tis…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
Can a blood test catch lupus flares earlier?
Diagnosis Not yet recruitingThis observational study tests whether levels of MPO-DNA complexes in the blood can serve as a reliable biomarker for disease activity in systemic lupus erythematosus (SLE). Researchers will compare MPO-DNA levels in 90 participants with active versus inactive lupus, and check ho…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
A PET tracer aims to reveal the brain inflammation MRI misses in MS
Diagnosis Not yet recruitingThis study tests whether a radioactive tracer called [18F]fluorodeprenyl-D2 can make chronic active lesions visible on PET scans in people with multiple sclerosis. These lesions are areas of ongoing brain inflammation that standard MRI often misses. Researchers will compare the P…
Sponsor: Parc de Salut Mar • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
A finger prick instead of a needle: could At-Home blood tests match hospital accuracy?
Diagnosis Not yet recruitingThis study tests whether blood samples collected at home using small capillary devices, like finger pricks, give the same results as traditional blood draws from a vein. Researchers will compare both methods in about 1,000 people with chronic conditions such as kidney disease, au…
Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
Painless blood test could replace bone marrow biopsy for MPN patients
Diagnosis Not yet recruitingThis study aims to develop a new blood test that could replace the invasive bone marrow biopsy currently used to diagnose myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will collect blood samples from 500 adults with suspected or confirmed MPN and anal…
Sponsor: Weizmann Institute of Science • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
AI reads biopsies to spot Crohn's patients at risk of surgery
Diagnosis Not yet recruitingResearchers are testing whether an artificial intelligence tool can measure fibrosis, or scarring, in intestinal biopsies from people with Crohn's disease. The study will use previously collected biopsy samples and medical records from 100 adults to see if the AI's fibrosis score…
Sponsor: PharmaNest, Inc • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Can a simple cone test predict fall risk in multiple sclerosis?
Diagnosis Not yet recruitingThis study evaluates whether the Cone Evasion Walk Test—a walking task that involves stepping around cones—is a reliable and valid way to assess balance, obstacle avoidance, and fall risk in people with multiple sclerosis (MS). Researchers will measure how consistent the test res…
Sponsor: Hacettepe University • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
A new ultrasound technique could spot hidden inflammation in psoriatic arthritis
Diagnosis Not yet recruitingThis study tests whether a newer ultrasound technique, shear wave elastography, can better detect inflammation at tendon and ligament attachment sites (entheses) in people with psoriatic arthritis compared to standard ultrasound. Researchers will compare imaging results from 60 p…
Sponsor: Marmara University • Aim: Diagnosis
Last updated Aug 27, 2026 00:00 UTC
-
A 5-Day genetic test could slash time to transplant for children with rare immune disease
Diagnosis Not yet recruitingThis trial tests whether a new ultra-rapid genetic test, using third-generation sequencing, can diagnose familial lymphohistiocytosis (FHL) in children within 5 days instead of the usual 6-8 weeks. FHL is a rare, life-threatening genetic condition where the immune system attacks …
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Stool test duo could revolutionize cancer surveillance in colitis
Diagnosis Not yet recruitingThis study tests whether combining two stool tests—fecal immunochemical test (FIT) and fecal calprotectin (FC)—can accurately detect precancerous or cancerous changes in people with long-standing ulcerative colitis. Participants will provide stool samples and then undergo a speci…
Sponsor: Qilu Hospital of Shandong University • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
A mobile x-ray van with AI could spot TB before it spreads
Diagnosis Not yet recruitingThis study tests a community-based screening strategy for tuberculosis (TB) in migrant communities in New York City. A mobile van offers digital chest X-rays with AI interpretation, along with TB symptom checks, blood tests for latent TB, and HIV testing. The goal is to see wheth…
Sponsor: Columbia University • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
Ultrasound may uncover hidden arthritis in IBD patients
Diagnosis Not yet recruitingThis study tests whether combining two screening questionnaires with a musculoskeletal ultrasound can detect spondyloarthritis—a type of inflammatory arthritis—in people who already have inflammatory bowel disease (IBD) but have not been diagnosed with arthritis. Two hundred adul…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Blood test plus symptom check may spare thousands from celiac biopsy
Diagnosis Not yet recruitingThis study aims to see if a blood test for TTG-IgA antibodies combined with symptom information can accurately sort adults into low, intermediate, or high risk for celiac disease. Researchers will analyze data from 15,500 patients who already had both a blood test and a duodenal …
Sponsor: The Cleveland Clinic • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase 1/2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
New Pill-Sized device could prevent dangerous blockages during gut scans
Diagnosis Not yet recruitingThis study tests a special capsule that patients swallow to check if their intestines are clear enough for a standard camera capsule. About 25 people with known or suspected intestinal narrowing will take part. They will swallow the patency capsule and get an X-ray within 30 hour…
Sponsor: AnX Robotica Corp. • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Urine test may replace colonoscopy for colitis patients
Diagnosis Not yet recruitingThis study looks at whether a substance in urine, called PGE-MUM, can show if ulcerative colitis is active or in remission. Researchers will collect urine and blood samples from 114 adults with confirmed ulcerative colitis and compare the results with colonoscopy findings. If suc…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
AI tool aims to cut allergy misdiagnosis in primary care
Diagnosis Not yet recruitingThis study tests whether AI-powered decision trees can help general practitioners better diagnose and manage allergies. About 600 patients with suspected allergies will be enrolled, and doctors will use an app that suggests next steps based on symptoms. The goal is to see if this…
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThis study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…
Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Tiny tweets, big impact? testing digital nudges to boost HIV prevention
Prevention Not yet recruitingResearchers at Emory University are running a rapid randomized controlled trial to see if small changes to digital messages and website design can help more people start and stay on HIV prevention medication (PrEP) through telehealth. The study includes adults in the United State…
Sponsor: Emory University • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Double probe heat therapy may slash cervical cancer risk in HIV-positive women
Prevention Not yet recruitingThis study will test if using two heat probes instead of one can better prevent cervical cancer in 300 women with HIV in Zimbabwe. The standard single-probe treatment often fails in these women. The goal is to see if the two-probe method is safe, acceptable, and more effective at…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Tweaking donor cells may shield older transplant patients from a dangerous complication
Prevention Not yet recruitingResearchers are testing whether removing a specific type of immune cell, called CD45RA-positive naive T cells, from donor stem cells can prevent graft-versus-host disease in older adults undergoing stem cell transplants for acute leukemia or myelodysplastic syndrome. The trial en…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Can delaying the second shingles shot boost protection for people on MS drugs?
Prevention Not yet recruitingPeople with multiple sclerosis or neuromyelitis optica spectrum disorder who take anti-CD20 drugs have a higher risk of shingles. The shingles vaccine is recommended for them, but the drug may weaken its effect. This trial compares two dosing schedules: one gives the second shot …
Phase 4 • Sponsor: University Hospital, Toulouse • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Aloe vera mouthwash tested against chemotherapy mouth sores
Prevention Not yet recruitingResearchers are studying whether aloe vera mouthwash can prevent or reduce the severity of oral mucositis, a painful mouth sore that often affects people receiving chemotherapy for acute leukemia. The trial compares aloe vera mouthwash plus usual care against usual care alone in …
Sponsor: Wake Forest University Health Sciences • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug stop the Body's attack after stem cell transplants?
Prevention Not yet recruitingThis phase II trial tests whether adding axatilimab to standard care can prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the recipient's body after a stem cell transplant. Adults with blood cancers receiving a myeloablative allogen…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
New probe technique could slash cervical cancer risk in HIV-Positive women
Prevention Not yet recruitingThis study tests whether using two probes during a heat-based treatment (thermal ablation) works better than the usual one-probe method to prevent cervical cancer in women living with HIV. About 200 women aged 25-49 with HIV and cervical precancer will be enrolled. The goal is to…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Two probes better than one? new study aims to cut cervical cancer in women with HIV
Prevention Not yet recruitingThis study will test whether using two heat probes instead of one to treat cervical precancer works better for women living with HIV. Researchers in Rwanda will enroll 300 women to see if the two-probe approach is safe, acceptable, and more effective at clearing HPV. The goal is …
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
Double probe heat therapy could slash cervical cancer risk in HIV-Positive women
Prevention Not yet recruitingThis study tests whether using two heat probes instead of one can better prevent cervical cancer in women living with HIV, who face a much higher risk. Researchers will enroll 300 women in Kenya to see if the two-probe method is safe, acceptable, and more effective at clearing HP…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
A steroid premedication may tame the immune reaction to a melanoma therapy
Prevention Not yet recruitingThis phase 2 trial tests whether a low dose of the steroid dexamethasone, given before the first four infusions of tebentafusp, can prevent cytokine release syndrome in people with advanced uveal melanoma. Tebentafusp is a standard first-line treatment for this eye cancer, but it…
Phase 2 • Sponsor: University of California, San Diego • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
Peer mentors may help women stay HIV-Free – trial tests new approach
Prevention Not yet recruitingThis trial tests whether a peer-led program that lets women choose and switch HIV prevention methods can increase consistent use compared to standard care. The program includes peer mentor support, HIV testing, access to PEP, and STI care. It enrolls HIV-negative women at elevate…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Can a 20-Minute video make teens Disaster-Ready?
Prevention Not yet recruitingThis trial tests whether a short, purpose-built educational video can strengthen high-school students' belief in disaster preparedness and their perception of disaster risk. About 144 students from twelve classes at one school in West Kalimantan, Indonesia, will be randomly assig…
Sponsor: Tanjungpura University • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Can a simple topical treatment stop a common Post-Surgery complication in ulcerative colitis?
Prevention Not yet recruitingThis trial tests whether applying 5-ASA (mesalamine) directly to the ileal pouch after surgery for ulcerative colitis can prevent pouchitis—a painful inflammation that affects more than half of patients. Adults with UC who are scheduled for pouch surgery are randomly assigned to …
Phase 4 • Sponsor: University Hospital, Linkoeping • Aim: Prevention
Last updated Aug 21, 2026 00:00 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 20, 2026 00:00 UTC
-
Olive oil as a shield? trial tests whether a daily spoonful cuts heart risks in HIV
Prevention Not yet recruitingThis trial asks whether taking 50 mL of extra virgin olive oil every day can reduce the chance of heart attacks, strokes, and related deaths in people living with HIV. About 1,300 adults aged 50–75 with well-controlled HIV and at least one heart risk factor will be randomly assig…
Sponsor: Fundacion SEIMC-GESIDA • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Tiny horses, big lessons: can ponies help kids tame diabetes?
Symptom relief Not yet recruitingResearchers are testing a diabetes education program that combines standard self-management lessons with hands-on activities involving miniature horses. Children and teens ages 8 to 20 with type 1 or type 2 diabetes, along with their caregivers, attend four sessions led by a diab…
Sponsor: Nemours Children's Clinic • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can an experimental injection ease the dryness and fatigue of Sjogren's?
Symptom relief Not yet recruitingResearchers are testing an experimental drug called ONO-4915 in adults with primary Sjogren's disease, a condition that causes dryness, fatigue, and pain. The trial enrolls about 60 people who have moderate to severe symptoms and a positive anti-SS-A/Ro antibody. Participants rec…
Phase 2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Cameras catch allergy relief: study puts faces under the lens
Symptom relief Not yet recruitingResearchers want to see whether facial photographs can show how well a fluticasone propionate nasal spray eases facial allergy symptoms. The study enrolls 16 adults with moderate to severe seasonal allergic rhinitis. Participants use the nasal spray and have their faces photograp…
Phase 4 • Sponsor: HALEON • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a Once-Daily moisturizer help psoriasis skin? patients put it to the test
Symptom relief Not yet recruitingResearchers are asking people with psoriasis to use Doublebase Once, a once-daily leave-on emollient, as their only moisturizer for about one month. Up to 100 adults across the UK join from home and answer online questionnaires about their skin and how the product feels to use. T…
Sponsor: Dermal Laboratories Ltd • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
New hope for stiff person syndrome: drug trial aims to ease muscle stiffness and improve walking
Symptom relief Not yet recruitingThis study tests a medicine called IGIV 10% (a type of antibody treatment) against a placebo in 38 adults aged 18-70 with Stiff Person Syndrome, a rare condition causing muscle stiffness and spasms. The main goal is to see if the drug helps people walk faster (measured by a 25-fo…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a smartphone app ease the Gut-Brain struggle for IBD patients?
Symptom relief Not yet recruitingThis study tests a mobile app designed to help Black and Hispanic adults with inflammatory bowel disease (IBD) manage stress and improve their quality of life. The app teaches coping skills, mindfulness, and disease acceptance. Researchers want to see if the app is practical and …
Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Exercise as a potential remedy for IBD-related fatigue
Symptom relief Not yet recruitingThis trial tests whether a personalized 6-month exercise program can reduce persistent fatigue in people with inflammatory bowel disease (IBD) who are in remission. Researchers will randomly assign 120 participants to either the exercise program or usual care. Fatigue levels are …
Sponsor: University Hospital, Grenoble • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a smartphone app help heal diabetic foot wounds?
Symptom relief Not yet recruitingResearchers are testing DiaFootCare, a mobile app that teaches foot self-care, sends medication and care reminders, guides users through taking wound photos, and shares information with pharmacists. The trial enrolls 139 adults aged 40 to 60 with diabetes and an active foot ulcer…
Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Could a simple wrist injection silence arthritis pain?
Symptom relief Not yet recruitingResearchers are testing whether a wrist nerve block, which uses a local steroid injection to interrupt pain signals, can reduce wrist pain in adults with rheumatoid arthritis. The trial enrolls 180 people with oligoarticular rheumatoid arthritis that affects the wrist. Participan…
Sponsor: Sohag University • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New biologic PRA-216 put to the test against stubborn eczema
Symptom relief Not yet recruitingResearchers are testing an experimental biologic drug called PRA-216 in adults with moderate to severe atopic dermatitis, a form of eczema. The trial compares PRA-216 with a placebo to see whether the drug is safe and can reduce eczema severity. Participants must have had eczema …
Phase 2 • Sponsor: Prana Therapies Inc • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Mind over gut: can meditation tame IBD Flare-Ups?
Symptom relief Not yet recruitingThis study tests whether an 8-week mindfulness-based stress reduction (MBSR) program can lower stress and improve well-being in people with inflammatory bowel disease (IBD). Seventy adults with mild-to-moderate IBD will either take the MBSR course online or watch an educational s…
Sponsor: Nova Scotia Health Authority • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Targeting hidden balance issues: a new therapy for early MS
Symptom relief Not yet recruitingThis trial tests whether a specialized form of physical therapy, called vestibular physical therapy, can improve balance in people with early multiple sclerosis (MS) who have mild disability but still feel unsteady. Participants will be randomly assigned to receive the therapy or…
Sponsor: LIFE - Research and Care Institute - Santa Lucia IRCCS • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Can a common antipsychotic keep cannabis users out of the ER?
Symptom relief Not yet recruitingThis trial tests whether giving patients a prescription for haloperidol to use as needed at home can help control symptoms of cannabinoid hyperemesis syndrome — a condition marked by severe nausea, vomiting, and abdominal pain from heavy cannabis use. The goal is to see if having…
Early phase 1 • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Virtual therapy targets the mind-gut link in IBD
Symptom relief Not yet recruitingThis study tests whether a 10-session virtual group psychotherapy program can help people with inflammatory bowel disease (IBD) who also have anxiety or depression. The therapy is adapted from a standard manual called Mind Over Mood and includes education on the brain-gut connect…
Sponsor: University of Chicago • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Your playlist as pain relief: new study tests music app for HIV-Related chronic pain
Symptom relief Not yet recruitingThis study tests whether a smartphone app that plays personalized music can help people with HIV manage chronic pain. Sixty participants will either use the music app daily for 3 months or receive educational materials about pain. The main goal is to see if the app is practical a…
Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Virtual reality mindfulness: a new way to ease stress in young adults with diabetes?
Symptom relief Not yet recruitingThis trial tests whether a virtual reality version of Mindfulness-Based Stress Reduction (MBSR-VR) can be delivered to young adults aged 16 to 20 with type 1 diabetes who report high stress. Participants will attend group sessions that teach meditation, body awareness, and mindfu…
Sponsor: Wayne State University • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Zapping the brain to loosen stiff legs and quiet nerve pain in MS?
Symptom relief Not yet recruitingThis trial tests whether a non-invasive brain stimulation technique called intermittent theta-burst stimulation (iTBS) can reduce lower-limb spasticity and neuropathic pain in people with multiple sclerosis. About 40 adults with MS and significant leg stiffness and pain will rece…
Sponsor: Comenius University • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
Can a smart order system ensure older AML patients get the support they need?
Symptom relief Not yet recruitingThis trial tests a method called Active Default to improve supportive care for adults 60 and older starting venetoclax-based therapy for acute myeloid leukemia (AML). Participants complete a geriatric assessment covering mobility, nutrition, mood, memory, and medications. If the …
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Could a daily glass of kefir soothe celiac gut troubles?
Symptom relief Not yet recruitingThis study asks whether drinking kefir every day can reduce gastrointestinal symptoms and improve quality of life in adults with celiac disease who follow a strict gluten-free diet. In a crossover design, 30 participants will consume 200 mL of kefir daily for four weeks, then con…
Sponsor: University Maribor • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Art as medicine: can drawing and painting help sick kids feel better about themselves?
Symptom relief Not yet recruitingThis trial tests whether a structured art therapy program, grounded in positive psychology, can improve self-compassion and hope in children aged 8 to 12 who are staying in a hospital ward. Half of the 80 participants will receive the art therapy sessions alongside standard nursi…
Sponsor: Suleyman Demirel University • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Can Brain-Training apps fix sleep in MS?
Symptom relief Not yet recruitingThis study tests whether AI-based cognitive training, using the Lumosity app, combined with a tailored physical-therapy program can improve sleep and quality of life in people with multiple sclerosis. Participants aged 25-40 with mild to moderate disability will undergo the train…
Sponsor: Cairo University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can an inhaled powder calm the painful Cold-Finger attacks of scleroderma?
Symptom relief Not yet recruitingThis study tests an inhaled powder called LIQ861 (treprostinil) in adults with scleroderma who have frequent, painful Raynaud's attacks—episodes where fingers or toes turn color and become numb or tingly. About 75 participants will be randomly assigned to receive either a dose th…
Phase 2 • Sponsor: Liquidia Technologies, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Mind over ache: could meditation tame MS pain?
Symptom relief Not yet recruitingThis trial tests whether a structured mindfulness program can reduce pain in adults with multiple sclerosis. Participants are randomly assigned to either the mindfulness group or an educational program, and their pain, fatigue, sleep, mood, and quality of life are tracked over se…
Sponsor: Hospital Universitario Virgen Macarena • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Zapping pain without drugs: brain stimulation put to the test for nerve pain
Symptom relief Not yet recruitingThis trial tests whether a non-invasive brain stimulation technique called temporal interference stimulation (tTIS) can reduce neuropathic pain—pain caused by nerve damage. Researchers will monitor changes in pain levels and brain plasticity in 60 adults with peripheral neuropath…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Could a 16-Week home exercise program change the course of early MS?
Symptom relief Not yet recruitingThis trial tests whether a 16-week remote physical activity program, including online newsletters and video coaching, can improve motivation and behavior in people newly diagnosed with multiple sclerosis (within the last 2 years). Participants will wear a Fitbit and log steps whi…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Can a new rowing seat help veterans with paralysis row freely?
Symptom relief Not yet recruitingThis trial compares two adaptive indoor rowing seats designed for Veterans who have limited trunk stability due to spinal cord injury, stroke, or neurodegenerative conditions. Participants will try both seats during short rowing sessions, and researchers will measure trunk moveme…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Sleep hormone melatonin put to the test against lupus fatigue and inflammation
Symptom relief Not yet recruitingThis trial investigates whether taking melatonin before bed can improve sleep quality, reduce fatigue, and lower inflammation in adults with active lupus. Sixty-four participants will either receive standard care plus melatonin or standard care alone for 12 weeks. Researchers wil…
Phase 2/3 • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Home workouts may rev up muscle energy in lupus patients
Symptom relief Not yet recruitingThis study tests whether a 16-week personalized home exercise program can improve muscle health and reduce fatigue in adults with stable lupus. Participants do three weekly sessions combining high-intensity interval training, strength exercises, and walking. Researchers measure c…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Brain training without drugs: can imagining movement ease MS pain?
Symptom relief Not yet recruitingThis study tests two types of brain training—motor imagery (mentally picturing movements) and sensorimotor training (repetitive sensory exercises)—against standard therapy for people with multiple sclerosis who have neuropathic pain in their legs. The goal is to see which approac…
Sponsor: Uludag University • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Could a squeeze of acid make gum Dark-Spot removal look better?
Symptom relief Not yet recruitingThis study tests whether applying citric acid during a procedure to remove dark gum pigmentation leads to better-looking results and faster healing. Adults aged 18 to 50 with natural dark gums will receive either standard depigmentation or depigmentation plus acid. The researcher…
Sponsor: Dijlah University • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Finger injections aim to loosen stiff hands in scleroderma
Symptom relief Not yet recruitingThis early-phase trial investigates whether monthly injections of hyaluronidase into the fingers can improve stiffness and hand function in people with systemic sclerosis who have sclerodactyly (tight, thickened skin on the fingers). The study enrolls 10 adults aged 18 to 60 and …
Early phase 1 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Could weekly yoga ease fatigue and pain in autoimmune disease?
Symptom relief Not yet recruitingThis study looks at whether a 12-session weekly yoga program, added to usual medical care, can help adults with systemic autoimmune and inflammatory diseases (like lupus) feel less tired, have less pain, and improve their mood. Researchers will also check if yoga helps people sti…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
AI coach for parents of diabetic kids: will it make carb counting easier?
Symptom relief Not yet recruitingThis study tests whether an AI-powered educational platform can help parents of children with type 1 diabetes count carbohydrates more accurately and manage diabetes better. About 80 parents will either use the AI platform plus usual care or usual care alone for 12 weeks. The goa…
Sponsor: Sultan Qaboos University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Could a bone drug ease pain in kids with rare inflammatory disease?
Symptom relief Not yet recruitingThis study tests whether the drug zoledronate can reduce pain in children aged 4 to 17 with chronic recurrent multifocal osteomyelitis (CRMO), a rare auto-inflammatory bone disease. The 30 participants have not responded to standard anti-inflammatory drugs. They will receive eith…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New rehab combo aims to ease MS fatigue and boost brain function
Symptom relief Not yet recruitingThis study tests whether a 12-week program combining individual physiotherapy, group movement-awareness sessions, and group psychotherapy can improve physical function, reduce fatigue, and enhance quality of life in 45 adults with multiple sclerosis. Each participant serves as th…
Sponsor: Charles University, Czech Republic • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Nurse-Led video calls aim to empower MS patients
Symptom relief Not yet recruitingThis study tests a six-month personalized telenursing program for 110 adults with multiple sclerosis. Participants receive monthly educational videos and nurse-led video calls to help them better understand their health and navigate the healthcare system. The goal is to improve h…
Sponsor: G. d'Annunzio University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Can a special diet tame ulcerative colitis? breath tests may tell
Symptom relief Not yet recruitingThis study tests whether a short liquid diet followed by a low-sulfur eating plan is safe and helpful for people with mild to moderate ulcerative colitis. Researchers will check if this approach improves gut health, lowers inflammation, and eases symptoms. They will also use brea…
Sponsor: University of British Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Could you help scientists unlock genetic cancer secrets?
Knowledge-focused Not yet recruitingThis study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?
Knowledge-focused Not yet recruitingResearchers are observing 300 adults aged 60 and older with inflammatory bowel disease who are starting an advanced therapy chosen by their usual care team. The study tracks immune-aging markers such as CD4/CD8 ratio and IL-6, along with frailty and nutrition, over 52 weeks. The …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
30 patients to test if nutrition tracking boosts wound healing
Knowledge-focused Not yet recruitingThis pilot study will check if it's possible to collect useful nutrition and health information from 30 adults with diabetic foot ulcers. Researchers want to see if they can recruit enough people and gather complete data. The goal is to learn about patients' diet, body compositio…
Sponsor: Hvidovre University Hospital • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists launch deep dive into IBD to uncover hidden clues
Knowledge-focused Not yet recruitingThis study will follow 100 adults with Crohn's disease, ulcerative colitis, or other IBD, plus their healthy relatives, for up to 3 years. Researchers will collect blood, stool, tissue samples, and imaging to track how immune cells and genetics change over time. The goal is to fi…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Two autoimmune conditions, one child: study probes hidden thyroid trouble
Knowledge-focused Not yet recruitingAutoimmune hepatitis makes a child's immune system attack their liver. Researchers at Assiut University Children's Hospital want to know how many children with this liver condition also develop thyroid disorders such as Hashimoto thyroiditis or Graves' disease. The team will test…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Cheap blood count ratios eyed as window into Myeloma's inflammatory grip
Knowledge-focused Not yet recruitingMultiple myeloma is a blood cancer in which abnormal plasma cells build up in bone marrow, and inflammation may shape how the disease behaves. Researchers at Assiut University plan to study 60 people newly diagnosed with myeloma before any anti-myeloma treatment begins. They will…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Migraines and tension headaches may be hidden companions to multiple sclerosis
Knowledge-focused Not yet recruitingResearchers at Assiut University Hospitals are studying how often adults with multiple sclerosis also get primary headaches such as migraine and tension-type headache. About 100 patients will complete a single visit that includes a neurological exam, headache history, disability …
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Triple-Pronged attack on gut inflammation put to the test
Knowledge-focused Not yet recruitingResearchers are testing whether blocking three inflammation pathways at once (TL1A, IL-23, and α4β7) calms inflamed intestinal tissue more effectively than blocking each pathway alone. The study enrolls 30 people: 10 with ulcerative colitis, 10 with Crohn's disease, and 10 withou…
Sponsor: PhoenixLAB srls • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New study tracks hidden dangers of common leukemia drug
Knowledge-focused Not yet recruitingThis study will follow 200 children with acute lymphoblastic leukemia or lymphoma to learn more about the short- and long-term side effects of asparaginase drugs. Researchers will track how often serious toxicities occur during standard treatment and a newer therapy called SJALL2…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Do social factors decide who completes lymphoma treatment?
Knowledge-focused Not yet recruitingResearchers are examining health records from adults diagnosed with diffuse large B-cell lymphoma, a fast-growing blood cancer, across multiple UK hospitals. The study asks whether a patient's ethnicity, level of socioeconomic deprivation, and other health conditions influence ho…
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can better aerobic fitness help MS patients keep their balance?
Knowledge-focused Not yet recruitingResearchers are studying whether aerobic fitness relates to walking, balance, and fatigue in people with multiple sclerosis. About 70 adults with relapsing-remitting or progressive MS will take walking tests and balance challenges that involve soft surfaces and head movements. Th…
Sponsor: Suleyman Demirel University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Real-World data sought on myeloma drug combo
Knowledge-focused Not yet recruitingThis study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant and are treated with a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The goal is to see how well this therapy works in e…
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Could stress make IBD treatments stop working?
Knowledge-focused Not yet recruitingThis study looks at how anxiety, depression, and stress might cause advanced IBD treatments to stop working. Researchers will ask 450 people with IBD to fill out questionnaires about their mental health while they receive regular infusions. The goal is to understand if mental hea…
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Are CLL patients getting fair referrals? new study investigates
Knowledge-focused Not yet recruitingThis study surveys primary care doctors and nurse specialists in the West Midlands to understand how they decide to refer patients with chronic lymphocytic leukemia (CLL) to specialists. The goal is to identify differences in referral practices and find ways to make care more equ…
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
UK launches first national vitiligo registry to monitor treatment safety
Knowledge-focused Not yet recruitingThis study creates a UK-wide registry for people with vitiligo, a skin condition causing white patches. It will track the safety and effectiveness of current treatments in up to 30 patients. The goal is to improve long-term care by collecting real-world data from dermatologists.
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Is your nose fueling infected eczema and scabies sores?
Knowledge-focused Not yet recruitingResearchers are studying where the bacteria that infect skin sores come from in people with scabies or atopic dermatitis. They will compare bacteria grown from infected skin lesions with bacteria from nasal swabs to see if the same species appear in both places. A group of health…
Sponsor: Istanbul Medeniyet University • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Which IBD therapy works best for kids? researchers compare two approaches
Knowledge-focused Not yet recruitingResearchers at Assiut University Children Hospital are comparing conventional and biologic therapies in children and adolescents with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The study tracks about 100 patients to measure clinical remission at…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Could metabolic syndrome shape the course of rare blood cancers?
Knowledge-focused Not yet recruitingResearchers at Assiut University are studying whether metabolic syndrome, a cluster of conditions like high blood pressure and high blood sugar, relates to the clinical course of chronic Philadelphia-negative myeloproliferative neoplasms. These are rare blood cancers where the bo…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
What happens to children with sudden paralysis? a new study seeks answers
Knowledge-focused Not yet recruitingThis study looks closely at children admitted to a hospital with acute flaccid paralysis, a condition causing sudden muscle weakness or paralysis. Researchers will collect information from routine medical care to describe the clinical features, possible risk factors, and outcomes…
Sponsor: Mohamed Aboelhamd Ali • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Tiny vesicles could hold the key to better islet transplants
Knowledge-focused Not yet recruitingResearchers are studying whether extracellular vesicles released by pancreatic islets can indicate islet quality and be used to improve their fitness before transplantation. The trial involves adults with type 1 diabetes who are on the waiting list for an islet transplant. The go…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
A breath of fresh air? stool 'Fingerprint' may predict IBD Flare-Ups
Knowledge-focused Not yet recruitingThis study is exploring whether a rapid, non-invasive stool test can help monitor inflammatory bowel disease (IBD) in children. The test uses a technology called differential mobility spectrometry (DMS) to analyze the molecular profile of stool samples. Researchers will compare t…
Sponsor: Tampere University Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Wearable patches could spot heart danger hiding in cancer treatment
Knowledge-focused Not yet recruitingThis pilot study is testing whether wearable patch monitors can help detect heart problems early in adults undergoing treatment for breast cancer, blood cancers, or multiple myeloma. Participants will wear two patches—one that tracks heart rhythm continuously and another that rec…
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Can Real-World data unlock better skin disease care?
Knowledge-focused Not yet recruitingThis observational study aims to collect and analyze data from up to two million patients with dermatologic conditions like vitiligo, atopic dermatitis, alopecia areata, and hidradenitis suppurativa, as well as their healthcare providers. By reviewing treatment patterns, outcomes…
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Staph bacteria may hold clues to painful skin rashes in IBD patients on Anti-TNF therapy
Knowledge-focused Not yet recruitingSome people with inflammatory bowel disease who take anti-TNF drugs develop painful rashes in skin folds and around the mouth, a condition called SPIDER. Researchers at a French hospital are studying whether levels of Staphylococcus aureus bacteria in these rashes change over six…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Eye damage in Graves' disease: can early clues predict who is at risk?
Knowledge-focused Not yet recruitingResearchers at the University of Copenhagen are studying why some people with newly diagnosed Graves' disease develop thyroid eye disease while others do not. The study follows about 430 participants for one year, collecting eye exams, blood and tear samples, and symptom question…
Sponsor: University of Copenhagen • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Hidden kidney damage may lurk in rheumatoid arthritis patients
Knowledge-focused Not yet recruitingResearchers are testing whether people with rheumatoid arthritis have early, symptom-free kidney problems more often than healthy people of the same age and sex. The study compares kidney function and urine protein levels between 120 participants, including those with rheumatoid …
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Do rheumatic diseases quietly damage the Eye's oil glands?
Knowledge-focused Not yet recruitingResearchers at Assiut University are studying whether rheumatic diseases such as rheumatoid arthritis, lupus, and Sjogren's syndrome harm the meibomian glands, the tiny eyelid glands that keep tears from evaporating. The study compares 120 people with these conditions to 30 healt…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Beyond peanuts: which legumes trigger childhood allergies?
Knowledge-focused Not yet recruitingResearchers at a French hospital are following 100 children aged 6 months to 17 years who are allergic to legumes other than peanut, such as peas, chickpeas, lentils, soy, lupin, and fava beans. The study tracks which legumes cause reactions, how old children are at first symptom…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Can three routine blood ratios predict who survives AML?
Knowledge-focused Not yet recruitingResearchers at Assiut University Hospitals are studying whether three blood measures predict survival in adults newly diagnosed with non-M3 acute myeloid leukemia. The measures are the ratio of C-reactive protein to albumin, the ratio of albumin to fibrinogen, and the level of fe…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
MRI scans may reveal hidden clues to myeloma relapse risk
Knowledge-focused Not yet recruitingThis study is looking at whether a special type of whole-body MRI can help predict how well people with multiple myeloma will do after a stem cell transplant. The MRI measures changes in bone marrow and fat content in the bones, which might indicate if the cancer is more likely t…
Sponsor: Fondazione EMN Italy Onlus • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Sugar tracer reveals how immune cells fuel up in the ICU
Knowledge-focused Not yet recruitingResearchers at Vanderbilt University Medical Center want to understand how immune cells use glucose, the body's main sugar, during critical illness. They give 25 adult ICU patients an intravenous infusion of a non-radioactive carbon-13 glucose tracer over a few hours. Then they c…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
New study aims to understand physical challenges in kids with nerve diseases
Knowledge-focused Not yet recruitingThis study will look at balance, core strength, leg strength, walking ability, and fatigue in 32 children aged 6-18 with demyelinating diseases (conditions affecting the protective coating of nerves). Each child will undergo a single session of non-invasive tests like balance exe…
Sponsor: Istanbul University - Cerrahpasa • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Could type 1 diabetes hide liver problems in children?
Knowledge-focused Not yet recruitingThis study looks at children and teenagers with type 1 diabetes to see how many have abnormal liver function tests. Researchers will check blood samples for signs of liver stress and try to find patterns or risk factors. The goal is to understand whether liver issues are common i…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Genetic test may flag type 1 diabetes risk years before symptoms
Knowledge-focused Not yet recruitingResearchers at Mass General Brigham are testing whether genetic information can help identify people who might benefit from early screening for type 1 diabetes, even before they feel sick. The study involves 150 adults from the MGB Biobank who agreed to be recontacted. Participan…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can a tiny capsule map the Gut's hidden microbes in IBD?
Knowledge-focused Not yet recruitingResearchers are testing a visual sampling capsule that collects fluid from different parts of the intestine without surgery. They will use it in 250 people, including those with active or remission Crohn's disease or ulcerative colitis, plus healthy volunteers. By analyzing the m…
Sponsor: Changhai Hospital • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can monthly selfies and symptom logs reveal how chronic skin diseases flare and settle?
Knowledge-focused Not yet recruitingThis study builds a long-term research cohort for people with psoriasis, eczema, or hidradenitis suppurativa. Participants use a certified app to answer symptom questions and take standardized photos of their skin once a month, with longer questionnaires twice a year. Trained ass…
Sponsor: Medisch Spectrum Twente • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can a Weight-Loss drug slow stomach emptying in type 1 diabetes?
Knowledge-focused Not yet recruitingThis phase 1 trial asks whether a single dose of tirzepatide changes how quickly the stomach empties in adults with type 1 diabetes who are overweight or have obesity. Researchers will give participants either tirzepatide or a placebo injection, then measure stomach emptying usin…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Immune 'hotness' and growth markers may sharpen lymphoma prognosis
Knowledge-focused Not yet recruitingThis study examines tissue samples from 70 people with diffuse large B-cell lymphoma and other aggressive B-cell lymphomas. Researchers will measure immune cell infiltration, called tumor 'hotness', and the Ki-67 proliferation index using two scoring methods. The goal is to see i…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can blood tests predict transplant complications?
Knowledge-focused Not yet recruitingThis study looks at how levels of immune-signaling molecules called cytokines change in the blood just before and after a stem cell transplant. Researchers want to see if these patterns differ based on the patient's disease, such as myelofibrosis or acute leukemia, and the type o…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study aims to predict deadly infections in blood cancer patients
Knowledge-focused Not yet recruitingThis study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
A patient questionnaire may rival lab tests for spotting rheumatoid arthritis flares
Knowledge-focused Not yet recruitingResearchers at Sohag University are studying 150 people with rheumatoid arthritis to see whether the Rheumatoid Arthritis Impact of Disease (RAID) questionnaire can reliably detect disease flares. They will compare the questionnaire's performance with other standard disease activ…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Can a drop of timothy grass unlock the Eye-Nose allergy link?
Knowledge-focused Not yet recruitingResearchers at Queen's University are testing a method to safely trigger eye allergies in a research setting. They will apply timothy grass extract to the eyes of allergic and non-allergic volunteers, then measure symptoms and collect tear and nasal fluid samples. The goal is to …
Sponsor: Queen's University • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Chemotherapy at home for leukemia: a feasibility test
Knowledge-focused Not yet recruitingThis study explores whether patients with acute myeloid leukemia can receive intravenous cytarabine chemotherapy at home instead of in the hospital. Researchers will track how many patients complete the planned home treatment, how often doses are given at home versus the hospital…
Sponsor: Zealand University Hospital • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Secret shoppers test if HIV stigma training works
Knowledge-focused Not yet recruitingThis study tests whether a multi-day training program can reduce stigma that doctors in Vietnam show toward people with HIV and men who have sex with men. Researchers will send trained actors ("standardized patients") to clinics to pose as real patients and measure how doctors tr…
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Could a tiny RNA molecule shed light on rheumatoid arthritis?
Knowledge-focused Not yet recruitingResearchers at Sohag University are comparing levels of a long non-coding RNA called GAS5 and a blood protein called IL-6 in people with rheumatoid arthritis versus healthy individuals. The study will measure GAS5 expression in blood samples using a technique called qRT-PCR and c…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can diet and blood tests predict IBD Flare-Ups?
Knowledge-focused Not yet recruitingResearchers at Assiut University are studying how nutrition, diet-related inflammation, and blood markers relate to disease activity in people with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. The study will enroll 100 adults aged 18 to…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New study aims to boost cervical cancer screening for women with HIV
Knowledge-focused Not yet recruitingThis study looks at how to make cervical cancer screening easier for women with HIV, who are at higher risk for this cancer. Researchers will talk to patients and doctors to find out what gets in the way of screening and follow-up care. They will also explore using HPV self-testi…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
A blood marker may reveal hidden heart risk in rheumatoid arthritis
Knowledge-focused Not yet recruitingThis study looks at whether a blood protein called asprosin is linked to metabolic syndrome and heart risk in people with rheumatoid arthritis. Researchers will compare asprosin levels in three groups: rheumatoid arthritis patients with metabolic syndrome, those without it, and h…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can a questionnaire capture the real burden of psoriatic arthritis?
Knowledge-focused Not yet recruitingResearchers at Assiut University are studying how psoriatic arthritis affects patients' daily lives and whether that impact matches clinical signs of disease activity. Adults with psoriatic arthritis will complete the Arabic version of the PsAID-12 questionnaire, which covers pai…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Stem cell harvest trial aims to unlock gene therapy for rare blood disorders
Knowledge-focused Not yet recruitingThis early-phase study at St. Jude Children's Research Hospital will test whether it is safe and possible to collect blood stem cells from 12 young adults with inherited bone marrow failure syndromes. Participants will receive two drugs (filgrastim and plerixafor) to move stem ce…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Could a hidden thyroid problem worsen rheumatoid arthritis?
Knowledge-focused Not yet recruitingResearchers are measuring how often subclinical hypothyroidism, a mild form of underactive thyroid, occurs in people with rheumatoid arthritis compared to healthy people. They will also check whether this thyroid condition relates to higher disease activity or more severe joint i…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can wearable glucose monitors reveal hidden risks in dialysis patients with diabetes?
Knowledge-focused Not yet recruitingThis study follows 100 adults with diabetes who are on peritoneal dialysis or about to start it. Researchers use a continuous glucose monitor to track blood sugar levels over time. They will look for links between glucose patterns and health events like hospitalizations, heart pr…
Sponsor: Elaine Chow • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can the immune system explain brain and psychiatric symptoms?
Knowledge-focused Not yet recruitingResearchers at King's College London are studying how the immune system relates to neuropsychiatric symptoms, which include mental and neurological issues. They will compare blood and spinal fluid samples from people with such symptoms against samples from healthy controls. The g…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can a tubeless 'Smart' insulin pump transform diabetes care for kids?
Knowledge-focused Not yet recruitingThis study looks at how children and teens with type 1 diabetes use the Omnipod 5, a tubeless insulin pump that automatically adjusts insulin based on glucose readings. Researchers will track how quickly families adopt the system, who chooses it, and how it affects blood sugar co…
Sponsor: Queen Fabiola Children's University Hospital • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Could celiac disease affect Children's heart rhythms?
Knowledge-focused Not yet recruitingThis study looks at whether children with celiac disease may have a higher risk of heart rhythm problems compared to healthy children. Researchers will measure specific heart rhythm intervals using an ECG in children diagnosed with celiac disease and compare them to healthy child…
Sponsor: Merna Fayez (Faiz) Shenoda • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Beyond swelling: could lymphedema be a Whole-Body biological disorder?
Knowledge-focused Not yet recruitingThis observational study aims to characterize the biological profile of primary and secondary lymphedema by measuring markers of inflammation, blood vessel health, metabolism, lymphatic function, and tissue scarring. It will compare 30 people with primary lymphedema, 30 with seco…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Can biological signals explain mastocytosis symptoms?
Knowledge-focused Not yet recruitingThis study aims to understand how symptoms of indolent systemic mastocytosis relate to biological signals in the body. Researchers will collect samples and data from 25 participants over 12 weeks to see how different treatments affect these signals. The goal is to improve underst…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Can immune fingerprints unlock new treatments for skin disease?
Knowledge-focused Not yet recruitingThis observational study aims to map the immune and molecular profiles of people with inflammatory skin conditions, including genetic forms like epidermolysis bullosa. By comparing these profiles to those of healthy individuals, researchers hope to identify unique signatures that…
Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Wireless glucose sensors could transform ICU care — but can they deliver?
Knowledge-focused Not yet recruitingThis study tests whether continuous glucose monitors (CGMs) like the Dexcom G7 can be safely and effectively used in intensive care units. The monitors provide real-time blood sugar readings and alarms for dangerously high or low levels, potentially reducing the need for frequent…
Sponsor: Imperial College Healthcare NHS Trust • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Blood tests could reveal who benefits from Next-Gen lymphoma antibodies
Knowledge-focused Not yet recruitingThis observational study is looking at whether biological markers in blood, tumor tissue, and imaging scans can predict how well patients with B-cell non-Hodgkin lymphoma respond to treatment with novel monoclonal antibodies. Researchers will collect samples from about 1,000 adul…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Blood's tiny messengers may expose hidden brain injury
Knowledge-focused Not yet recruitingThis study investigates whether tiny particles called extracellular vesicles, released by brain cells into the blood, can serve as reliable markers of nerve damage in people with multiple sclerosis or stroke. Researchers will measure these particles in blood samples from 60 parti…
Sponsor: Roberto Furlan • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can a Life-Saving transplant leave hidden scars on a Child's mind?
Knowledge-focused Not yet recruitingThis study looks at children aged 6 to 8 who had a stem cell transplant at least two years ago to treat a primary immunodeficiency—a genetic condition that weakens the immune system. Researchers will use standardized tests and interviews to measure the children's thinking skills,…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Hidden MS progression: can brain scans and blood tests predict it?
Knowledge-focused Not yet recruitingThis study follows 180 people with early relapsing-remitting multiple sclerosis (MS) to understand why some experience disability progression even without relapses. Researchers will use MRI scans, eye tests, and blood biomarkers to see if they can predict this type of progression…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can 3D-Printed models unlock personalized blood cancer therapies?
Knowledge-focused Not yet recruitingThis study aims to create 3D models of B-cell cancers—like chronic lymphocytic leukemia, splenic marginal-zone lymphoma, and hairy cell leukemia—using blood samples from patients. The goal is to build realistic models that mimic the tumor environment, which could help researchers…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a smart tool keep watch on leukemia after treatment stops?
Knowledge-focused Not yet recruitingThis study explores whether a digital tool can help monitor adults with chronic myeloid leukemia who have stopped treatment for up to two years. Over 12 months, researchers will track how often patients use the tool, aiming for a usage rate of at least 60%. The goal is to see if …
Sponsor: Versailles Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Immune clues in the blood may foretell heart trouble
Knowledge-focused Not yet recruitingThis study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could a simple protein test unlock the secrets of joint disease?
Knowledge-focused Not yet recruitingThis study looks at whether levels of a protein called 15-PGDH in the blood and joint fluid are linked to the severity of osteoarthritis and ankylosing spondylitis. Researchers will measure 15-PGDH in about 51 adults with these conditions and compare it with ultrasound images and…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Engineering immune cells to outsmart Leukemia's defenses
Knowledge-focused Not yet recruitingThis study investigates how to engineer T cells to more effectively target acute myeloid leukemia (AML). Researchers will analyze samples from healthy donors and AML patients to identify T-cell receptors that recognize leukemia cells. The goal is to create next-generation enginee…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Could a protein blocker quiet Leukemia's alarm system?
Knowledge-focused Not yet recruitingThis study investigates whether blocking a protein called IRAK4 can disrupt TLR signaling in leukemia cells from people with chronic lymphocytic leukemia (CLL). Researchers will collect extra blood samples from 50 adults with CLL during routine blood tests. In the lab, they will …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Rewiring the immune system: a new hope for children with severe IBD?
Knowledge-focused Not yet recruitingThis study investigates why children with inflammatory bowel disease (IBD) have an overactive immune response in the gut, and whether blood stem cells can be engineered to restore tolerance. Researchers will analyze blood and intestinal tissue samples from 80 children with IBD, w…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Does CAR-T therapy affect the brain? a study investigates
Knowledge-focused Not yet recruitingThis study follows people with relapsed or refractory multiple myeloma who are scheduled to receive BCMA CAR-T therapy, a type of cell treatment. Researchers will test memory, attention, and other thinking skills at the start and again at 1, 6, and 12 months after the infusion. T…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
A simple Note-Taking change could transform blood cancer care
Knowledge-focused Not yet recruitingThis quality improvement initiative tests whether a standardized electronic medical record template for progress notes, combined with a pharmacist-led medication titration service, can improve the management of polycythemia vera (PV). The study enrolls hematologists and oncologis…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can mapping fish allergy profiles in kids improve diagnosis?
Knowledge-focused Not yet recruitingThis study follows 120 children and adolescents in Spain who have been newly diagnosed with IgE-mediated fish allergy. Researchers will collect data on symptoms, test results, and molecular sensitization patterns to better understand how fish allergy presents in this population. …
Sponsor: Carmelo Escudero • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Could a daily walk shield the brain's wiring in aging MS patients?
Knowledge-focused Not yet recruitingThis study investigates whether physical activity and other lifestyle factors are linked to changes in myelin—the protective coating around nerve fibers—in people aged 50 to 70 who have had multiple sclerosis for over a decade. Participants will undergo MRI scans to measure myeli…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Amniotic cell secretions may fight gut inflammation and scarring — a lab study puts them to the test
Knowledge-focused Not yet recruitingThis lab study tests whether a cell-free mixture of molecules and particles released by human amniotic mesenchymal stromal cells can reduce inflammation, prevent scarring, and promote healing in gut tissue from people with inflammatory bowel disease (Crohn's disease or ulcerative…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Ultrasound and blood markers may unlock personalized treatment for rare nerve disease
Knowledge-focused Not yet recruitingThis study investigates whether nerve ultrasound patterns and biomarkers in blood and spinal fluid can predict how people with chronic inflammatory demyelinating polyneuropathy (CIDP) respond to treatment. Researchers will follow 30 adults with CIDP, including newly diagnosed and…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Can better detection of precancerous lesions in IBD prevent colorectal cancer?
Knowledge-focused Not yet recruitingPeople with inflammatory bowel disease (Crohn's disease or ulcerative colitis) have a higher risk of developing colorectal cancer. This study follows 800 adults with IBD who need a screening colonoscopy to look for precancerous growths called dysplasia. Researchers aim to underst…
Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Blood particles may reveal hidden clues to scleroderma complications
Knowledge-focused Not yet recruitingThis study looks at how tiny particles called extracellular vesicles travel through the bloodstream in people with systemic sclerosis, an autoimmune disease that affects blood vessels and organs. Researchers will take blood samples from different points in the circulation to see …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
CAR-T breakthroughs come with infection risks – new study aims to decode them
Knowledge-focused Not yet recruitingThis study follows adults with multiple myeloma or B-cell lymphoma who receive CAR-T cell therapy, a powerful immune treatment. Researchers track infections that occur in the first year after treatment, looking at how common they are, what causes them, and which factors raise the…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Does the setting of care affect whether kids finish their antibiotics?
Knowledge-focused Not yet recruitingThis observational study looks at whether children aged 3 months to 16 years are more likely to complete their full course of antibiotics when prescribed at a primary care clinic versus a hospital emergency department. Researchers surveyed parents by phone after treatment ended t…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple blood test predict lupus in children with ITP?
Knowledge-focused Not yet recruitingThis study looks at children with immune thrombocytopenic purpura (ITP) who also have certain antibodies, as they are at higher risk of developing lupus. Researchers will analyze blood samples to track immune cell changes and markers that may signal the transition to lupus. The g…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Could early markers unlock treatments for a rare childhood disease?
Knowledge-focused Not yet recruitingThis study follows babies and young children (up to age 5) who have a genetic diagnosis of ataxia telangiectasia (A-T), a rare disease that affects movement and immunity. Researchers use brain and lung scans, blood tests, and movement analysis to spot early signs of disease progr…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Skin disease evolution under the microscope: a 17-Year look at what drives severity
Knowledge-focused Not yet recruitingThis study follows 5,000 people with common inflammatory skin conditions—like eczema, psoriasis, and hidradenitis suppurativa—over up to 17 years to see how their disease severity changes. Researchers will collect medical history, treatments, and symptom scores to identify factor…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Genetic clues may forecast multiple sclerosis after vision loss
Knowledge-focused Not yet recruitingThis observational study looks at whether combining genetic information with standard clinical data can better predict who will develop multiple sclerosis after a first episode of optic neuritis (inflammation of the optic nerve). Researchers will follow 180 people aged 16 and old…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Newborn SCID screening study aims to unlock secrets of immune disorders
Knowledge-focused Not yet recruitingThis study follows infants who had a positive newborn screening test for severe combined immunodeficiency (SCID), a group of genetic disorders that leave babies vulnerable to life-threatening infections. Researchers will track these children to identify the underlying causes of t…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Blood fats and nanoparticles may reveal hidden clues in autoimmune liver disease
Knowledge-focused Not yet recruitingThis study looks at two types of liver disease — autoimmune hepatitis and non-alcoholic fatty liver disease — to see if fats in blood cells and tiny particles called extracellular vesicles differ between them. Researchers will collect blood samples from 24 adults and analyze thes…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Scientists target GLUT1 to tame immune attacks in type 1 diabetes
Knowledge-focused Not yet recruitingThis study investigates whether blocking GLUT1, a protein that helps immune cells use sugar, can reduce the autoimmune attack that destroys insulin-producing cells in type 1 diabetes. Researchers will analyze stored blood samples from adults with type 1 diabetes and test immune c…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Migrant HIV study: does social status shape treatment success?
Knowledge-focused Not yet recruitingThis study looks at how a person's migration history and social situation affect how well HIV treatment works. Researchers will compare the health outcomes of 150 migrants living with HIV in France, based on their social and administrative status. The goal is to understand whethe…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
New glucose monitor aims for pinpoint accuracy in diabetes care
Knowledge-focused Not yet recruitingThis pilot study tests a new continuous glucose monitor (CGM) called SAVA in 20 adults with Type 1 Diabetes. Participants wear three SAVA sensors and one standard sensor for 15 days to check how well the SAVA measures blood sugar compared to lab tests. The study also looks at com…
Sponsor: SAVA Technologies Ltd. • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
Knowledge-focused Not yet recruitingThis study investigates sexual and urinary problems in people with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness. While visible symptoms like droopy eyelids are well-known, issues like sexual dysfunction and bladder problems are often ignored. R…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Genetic clue may unlock why lupus hits some people harder
Knowledge-focused Not yet recruitingThis study investigates whether a specific gene variation (ICOS) is linked to developing systemic lupus erythematosus (SLE) and how severe the disease becomes. Researchers will analyze blood samples from 30 people diagnosed with SLE to look for patterns in the ICOS gene. The goal…
Sponsor: South Valley University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Home devices may spot lung flare-ups before they become emergencies
Knowledge-focused Not yet recruitingThis study tests whether people with fibrotic interstitial lung disease can use home monitoring devices—like a spirometer, pulse oximeter, and scale—to help detect serious lung events such as flare-ups or hospitalizations. About 200 participants will use these devices connected t…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Could HIV treatment choice affect sleep? new study investigates
Knowledge-focused Not yet recruitingThis study looks at sleep health in people with HIV who are on different antiretroviral therapies. Some participants switch from a dolutegravir-based regimen to a doravirine-based one, while others stay on dolutegravir. Sleep is measured using questionnaires, wrist-worn activity …
Phase 4 • Sponsor: University of Witwatersrand, South Africa • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Smartwatches may spot IBD flares before symptoms start
Knowledge-focused Not yet recruitingThis study explores whether changes in heart rate, sleep, and activity measured by a person's own smartwatch can predict flare-ups in inflammatory bowel disease (IBD). Six hundred adults with Crohn's disease or ulcerative colitis who already own a compatible device will participa…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Baby blood test could predict type 1 diabetes risk
Knowledge-focused Not yet recruitingThis study aims to identify newborns with a high genetic risk of developing type 1 diabetes. Researchers will screen 50,000 infants using a simple genetic test to find those with a greater than 10% risk. The goal is not to treat diabetes, but to find eligible babies for future pr…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can AI predict heart trouble in IBD patients?
Knowledge-focused Not yet recruitingThis study looks at people with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, to better understand their risk of serious heart problems like stroke and heart attack. Researchers will collect information on therapy, disease activity, lifestyle…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Phone vs. mail: which gets more people to screen for type 1 diabetes?
Knowledge-focused Not yet recruitingThis study compares two ways of inviting people to screen for type 1 diabetes at home: a simple email or letter versus a personal phone call. Researchers want to see which method leads more people to complete and return a home screening kit. Participants are adults and children a…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Simple CT scan could reveal hidden heart risks in HIV patients
Knowledge-focused Not yet recruitingThis study investigates whether a simple coronary CT scan can detect early signs of heart disease in people with HIV. Researchers will measure calcium buildup in the heart arteries of 384 Mexican adults with HIV who have undetectable viral loads. The goal is to better understand …
Sponsor: Instituto Mexicano del Seguro Social • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
Knowledge-focused Not yet recruitingThis study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study to reveal hidden immune effects of common leukemia drug
Knowledge-focused Not yet recruitingThis study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hemp seed allergy risk under the microscope: new study launches
Knowledge-focused Not yet recruitingThis study will test 35 people with known or suspected allergies to cannabis, tree nuts, or seeds to see if they are also allergic to hemp seeds. Participants will receive skin prick tests and blood tests to measure allergic reactions. The goal is to understand the potential alle…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test could predict bleeding risk in cancer patients
Knowledge-focused Not yet recruitingThis study aims to create a score that uses a special blood test to predict bleeding risk in people with blood cancers and very low platelet counts. Researchers will take an extra blood sample from 410 participants and analyze it with viscoelastometric tests. The goal is to ident…
Sponsor: Centre Hospitalier Annecy Genevois • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists build lab models of scleroderma from Patients' blood cells
Knowledge-focused Not yet recruitingThis study aims to create stem cell lines from blood samples of 16 people: 4 with severe scleroderma, 4 with mild scleroderma, and 8 of their healthy relatives. These stem cells will be turned into various tissue types (like heart, skin, and immune cells) in the lab to study how …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could blocking TL1A stop skin scarring in scleroderma? early lab study hints at possibility
Knowledge-focused Not yet recruitingThis study will test if blocking a protein called TL1A can reverse skin scarring in systemic sclerosis, a rare autoimmune disease. Researchers will take blood and skin samples from 10 patients with early diffuse scleroderma and 10 healthy people. They will treat the samples in th…
Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New study tests if SPECT imaging can forecast prostate cancer treatment success
Knowledge-focused Not yet recruitingThis study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-base…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
HIV and fatty liver: scientists hunt for hidden clues in the blood
Knowledge-focused Not yet recruitingThis study looks at how HIV might change the way the body handles fats in the liver, leading to fatty liver disease. Researchers will collect one blood sample from 120 adults: people with HIV and fatty liver, people without HIV but with fatty liver, and healthy controls. By analy…
Sponsor: Yinzhong Shen • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Massive MS study aims to unlock secrets of disability progression
Knowledge-focused Not yet recruitingThis study will follow 2,000 people with multiple sclerosis (MS) for five years to understand why some get worse faster than others. Researchers will use brain scans, eye exams, blood tests, and activity monitors to track changes. The goal is to find factors—like inflammation, bl…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC